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1. Summary 
 
Amino acids play a critical role in the body as they constitute the building blocks of proteins 
and fulfill many other functions. The absorption of amino acids from the diet across small 
intestine enterocytes and the reabsorption of amino acids from the kidney glomerular filtrate 
are critical features that allow maintenance of the body’s amino acid supply. 
 
B0AT1 (Slc6a19) is responsible for the uptake of a broad range of neutral amino acids across 
the apical membrane of kidney proximal tubule cells and small intestine enterocytes. 
In kidney, we have shown in a collaborative study that correct apical expression of B0AT1 
and of other SLC6 family members B0AT3/XT2 (Slc6a18), XT3 (Slc6a20b) and XT3s1/SIT1 
(Slc6a20a) is controlled by the associated protein Tmem27/Collectrin (Danilczyk et al, 2006). 
In the small intestine, we have shown in the present work that it is not Tmem27 but a 
homologue, the angiotensin-converting enzyme 2 (ACE2) that associates to B0AT1. This 
association was demonstrated in ace2 null mice as they lack B0AT1 expression at the apical 
membrane of enterocytes. Furthermore, direct interaction between these two proteins was 
shown by co-immunoprecipitating ACE2 from small intestine brush border membranes with 
an antibody against B0AT1. Study of the phenotype of ace2 null mice evidenced a specific 
decrease in plasma glycine and L-tryptophan levels. Surprisingly, this was accompanied by 
an increase of L-lysine levels. Although the food intake of ace2 null mice is similar to that of 
their wild-type littermates, they display a lower body weight at 8 weeks that originates from a 
slower weight gain after weaning. 
Mutations in B0AT1 have been shown to be causative of most cases of Hartnup disorder. We 
have shown that some of these mutations differentially interact with the associated proteins 
Tmem27 and ACE2, and postulate that this participates to the phenotypic heterogeneity of 
Hartnup disorder. 
Altogether, our results show that B0AT1 expression is controlled by tissue-specific associated 
proteins Tmem27 in kidney and ACE2 in small intestine. Interestingly, ACE2 has in contrast 
to Tmem27, a catalytic domain and plays a key role in the regulation of angiotensin II levels. 
This raises exciting questions concerning the regulation of amino acid transport by the renin 
angiotensin system that is involved in blood pressure regulation. 
 
B0AT3/XT2 (Slc6a18) has remained an “orphan transporter” since its identification in 1998. It 
localises to the later portion of the kidney proximal tubule in a complementary manner to the 
related B0AT1 transporter (52% identity) where as B0AT1 it associates to Tmem27 for correct 
apical localisation. The function of B0AT3 as an amino acid transporter was only hinted after 
generation of the knock-out mouse model that displayed glycinuria (Quan et al, 2004). 
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However, direct evidence of amino acid transport was not generated as no substrate uptake 
was measured in X. laevis oocytes or other expression systems. 
Co-expressing B0AT3 with ACE2 in X. laevis oocytes, but intriguingly not with Tmem27, we 
succeeded in measuring a broad range amino acid transport (A, M, V, I > G, S, L). Further 
characterisation showed that L-isoleucine is transported with a relatively high affinity (K0.5 = 
0.21 mM compared to K0.5 = 0.71 mM for B0AT1) in a Na+ and Cl- -dependant and pH-
independent manner. The organisation and the kinetics of the neutral amino acid 
transporters along the proximal tubule are therefore fitting to the decreased neutral amino 
acid content of the lumen along the proximal tubule with the expression of the higher affinity 
B0AT3 in the later segments of the proximal tubule. 
As expected, B0AT3 expression in proximal kidney tubule was normal in ace2 null mice 
confirming that Tmem27, and not ACE2, is necessary for correct expression of B0AT3 in 
kidney proximal tubule cells. To assess B0AT3 function, we re-analysed the Slc6a18 (B0AT3) 
knock-out mouse model after more than 10 generations of backcrossing into the C57BL/6 
strain. Next to the previously published glycinuria, we observed a urinary loss of several 
other amino acids, in particular of beta-branched and small neutral ones. Using telemetry 
measurements, we confirmed the previously described link of B0AT3 absence with 
hypertension but only in physically restrained animals. 
Taken together, the data indicate that formerly orphan transporter XT2 functions as a Na+ 
and Cl- -dependent neutral amino acid transporter that we renamed B0AT3. 
3 
2. Zusammenfassung 
 
Aminosäuren spielen eine wichtige Rolle im Körper, da sie die Bausteine der Proteine 
darstellen und zusätzlich viele andere Funktionen erfüllen. Die Absorption von Aminosäuren 
aus der Nahrung durch die Enterozyten des Dünndarms und die Reabsorption der 
Aminosäuren aus dem glomerulären Filtrat der Nieren, sind kritische Funktionen, die die 
Erhaltung der Versorgung des Körpers mit Aminosäuren erlauben. 
 
B0AT1 (Slc6a19) ist für die Aufnahme einer Vielfalt von neutralen Aminosäuren über die 
apikale Membran von proximalen Tubuluszellen der Niere und der Enterozyten des 
Dünndarms verantwortlich. In einer kollaborativen Studie haben wir gezeigt, dass die 
korrekte apikale Expression von B0AT1 und anderer SLC6 Familienmitglieder wie B0AT3/XT2 
(Slc6a18), XT3 (Slc6a20b) und XT3s1/SIT1 (Slc6a20a) in der Niere durch das assoziierte 
Protein Tmem27/Collectrin (Danilczyk et al, 2006) kontrolliert wird. 
In dieser aktuellen Arbeit haben wir gezeigt, dass es im Dünndarm nicht Tmem27 ist, 
sondern ein Homolog, das Angiotensin-Converting Enzyme 2 (ACE2), welches mit B0AT1 
assoziiert. Diese Assoziation wurde in ace2 null Mäusen gezeigt, da sie in der apikalen 
Membran der Enterozyten keine B0AT1 Expression haben. Des Weiteren wurde die direkte 
Interaktion der beiden Proteine durch Co-Immunopräzipitation von ACE2 aus 
Bürstensaummebranen des Dünndarms mittels eines Antikörpers gegen B0AT1 gezeigt. 
Untersuchungen des Phänotyps von ace2 null Mäusen erwiesen eine spezifische Senkung 
der Plasmakonzentrationen von Glycin und L-Tryptophan. Erstaunlicherweise ging dies mit 
einem Anstieg der L-Lysin-Werte einher. Obwohl die Nahrungsaufnahme der ace2 null 
Mäuse ähnlich ist, wie die der Wildtyp Wurfgeschwister, weisen sie nach 8 Wochen ein 
kleineres Körpergewicht auf, welches auf eine langsamere Gewichtszunahme 
zurückzuführen ist. 
Mutationen in B0AT1 haben sich als die Ursache der meisten Fälle der Hartnup Krankheit 
erwiesen. Wir haben gezeigt, dass einige dieser Mutationen, auf verschiedene Weise, mit 
den assoziierten Proteinen Tmem27 und ACE2 interagieren, und postulieren, dass dies zur 
phänotypischen Heterogenität der Hartnup Krankheit beiträgt.  
Insgesamt zeigen unsere Resultate, dass die Expression von B0AT1 durch 
gewebespezifische assoziierte Proteine reguliert wird, Tmem27 in der Niere und ACE2 im 
Dünndarm. Interessanterweise hat ACE2 im Unterschied zu Tmem27 eine katalytische 
Domäne und spielt eine Schlüsselrolle in der Regulation der Angiotensin II Werte. Dies führt 
zu weiteren spannenden Fragen betreffend der Regulation von Aminosäuretransport durch 
das Renin-Angiotensin-System, welches in die Regulation des Blutdruckes involviert ist. 
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B0AT3/XT2 (Slc6a18) ist ein so genannter “orphan transporter” geblieben seit seiner 
Entdeckung 1998. Dieser Transporter ist in den späteren Teilen des proximalen Tubulus der 
Niere zu finden, seine Lokalisation ist komplementär zu derer des verwandten B0AT1 
Transporters (52% Identität). Sowohl B0AT3 als auch B0AT1 werden mit Tmem27 assoziiert 
vorgefunden, welches sich als notwendig für eine korrekte apikale Lokalisation herausgestellt 
hat. Ein möglicher Aminosäuretransport durch B0AT3 wurde nur durch Verwendung des 
knockout-Maus-Modells angedeutet, welches Glycinuria zeigte (Quan et al, 2004). Ein 
direkter Beweis war allerdings nicht möglich, da in X. laevis Ooozyten oder anderen 
Expressionssystemen keine Aufnahme von Substrat messbar war. 
Durch die Co-Expression von B0AT3 mit ACE2 in X. laevis Oozyten, aber nicht mit Tmem27, 
waren wir in der Lage eine grosse Vielfalt von Aminosäurentransport zu messen (A, M, V, I > 
G, S, L). Weitere Charakterisierung zeigte dass L-Isoleucin mit einer relativ hohen Affinität 
(K0.5 = 0.21 mM verglichen mit K0.5 = 0.71 mM für B0AT1) auf eine Na+ und Cl- -abhängige und 
pH-unabhängige Art transportiert wird. Die Organisation und die Kinetik des Transports 
neutraler Aminosäuren entlang des proximalen Tubulus passen daher zum erniedrigten 
Gehalt an neutralen Aminosäuren im Lumen entlang des proximalen Tubulus, wobei der 
höher affine B0AT3 Transporter in den späteren Segmenten des proximalen Tubulus 
exprimiert ist. 
Wie erwartet war die B0AT3 Expression im proximalen Nierentubulus in den ace2 null 
Mäusen normal, dies bestätigt, dass Tmem27 und nicht ACE2 notwendig sind, für die 
korrekte Expression von B0AT3 in den proximalen Nierentubuluszellen. Um die Funktion von 
B0AT3 zu bestimmen haben wir nochmals das Slc6a18 (B0AT3) knockout-Maus-Modell nach 
mehr als 10 Rückkreuzungsgenerationen mit dem C57BL/6 Stamm analysiert. 
Neben der bereits zuvor publizierten Glycinuria, haben wir den Verlust verschiedener 
anderer Aminosäuren in den Urin beobachtet, insbesondere von beta-verzweigten und 
kleinen neutralen Aminosäuren. Unter Verwendung von Telemetrie-Messungen haben wir 
den zuvor beschriebenen Zusammenhang zwischen der Abwesenheit von B0AT3 mit 
Bluthochdruck bestätigt, dies jedoch nur in physisch eingeschränkten Tieren. 
Zusammenfassend zeigen die Daten, dass der ehemals als „orphan transporter“ 
beschriebene XT2 als Na+ und Cl- -abhängiger neutraler Aminosäurentransporter 
funktioniert, welchen wir aufgrund dieser Eigenschaften in B0AT3 umbenannt haben. 
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3. General Considerations on Nutrition 
 
3.1 Metabolism and Energy 
 
The body’s metabolism is the set of chemical processes involved in energy production, 
energy release and growth that are necessary to maintain life. The first law of 
thermodynamics states that total energy in a closed system is constant. The energy acquired 
by the body is used to fuel a variety of processes described in figure 1, accounting for a 
basal metabolic rate of about 30 kcal / kg body weight / day. Additionally, the second law of 
thermodynamics states that chemical transformations lead to loss of free energy. The body 
therefore continuously requires new sources of energy, which in humans is mostly acquired 
from ingested food.  
The western diet consists of 55-60% carbohydrates, 25-30% fat and 10-15% proteins. Each 
of these compounds can be digested to smaller molecules that are absorbed in the small 
intestine. The fate of sugars, lipids and amino acids will depend on the body’s energy 
requirements. These compounds can either be used for the synthesis of new molecules, 
converted to energy or stored. Carbohdydrates and lipids can be glycolysed (in muscle and 
liver) and beta-oxidized (in liver), respectively, before integration in the citric acid cycle and 
oxidative phosphorylation. These metabolic pathways lead to the synthesis of adenosine 
triphosphate (ATP), that contains high energy in one of its phosphate bonds. The integration 
of amino acids in energy metabolism will be discussed further in section 3.3. Carbohydrates 
can be stored as glycogen in muscle or liver, triglycerides in the adipocytes of fat tissue (and 
partly in muscle) and amino acids as proteins in muscle (Boron & Boulpaep, 2005). 
 
 
3.2 General Considerations on Proteins 
 
Proteins are essential for nutrition because of the constituent amino acids that make up all 
the synthesised proteins of the body. Though it was generally believed that animal proteins 
were exclusively constituted of L-amino acids, D-amino acids are also physiologically 
relevant. D-serine acts as a neurotransmitter in the brain (Wolosker et al, 2008), and D- to L-
aspartic acid ratio increases in elderly tissue, modifying protein structure (Fujii, 2005). This 
remains the exception and amino acids mentioned all through the text refer to L-amino acids, 
unless otherwise specified. 
The western diet daily supplies about 0.8 g protein / kg body weight, which can be converted 
to 4.3 kcal / g of amino acids. Proteins account for 14% of the body mass, and are distributed 
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throughout the body with 40% in muscle, 25% in body organs, and the remaining mostly in 
skin and blood. From all the proteins contained in the body, half can be mobilised as a fuel 
source. However, since most proteins have roles in structure or function, only 5% of the 
resting energy comes from proteins, which may be increased up to 15% in starvation 
conditions (Boron & Boulpaep, 2005; Gropper et al, 2005). 
 
 
  
 
Figure 1. Energy balance (Boron & Boulpaep, 2005). 
 
 
Protein functional categories 
 
Enzymes: Catalyse chemical reactions and allow, among others, digestion, tissue energy 
production, blood coagulation, excitability and contractility of neuromuscular tissue. 
Hormones (except steroid hormones): Act as chemical messengers by binding to a receptor 
and generally regulate metabolic processes (insulin, glucagon). They are synthesised and 
secreted by endocrine tissues (glands). Amino acids are often precursors for hormone 
synthesis like tyrosine for catecholamine synthesis and tryptophan for melatonin synthesis. 
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Structural proteins: Contractile proteins (actin and myosin) or fibrous proteins present in 
bone, teeth, skin, tendons, cartilage, blood vessels, hair and skin (collagen, elastin, keratin). 
Immunoproteins: Protect the organism against disease (immunoglobulins or antibodies). 
Transport proteins: Transport specific substrates in blood (albumin), within cells, or across 
the membrane (amino acid transporters). 
Other functions: Blood pH buffering or conjugation of proteins with non-protein components 
to form glycoproteins (mucus, connective tissue), proteoglycans (extracellular matrix, bone, 
cartilage), lipoproteins (chylomicrons, very low / low / high density lipoproteins), flavoproteins 
(redox potential) and metalloproteins (enzymatic or transport functions) (Gropper et al, 2005). 
 
 
3.3 Amino Acid Metabolism 
 
Once taken up by the small intestine as free amino acids or small peptides (see section 4.3), 
most amino acids are released in the portal circulation either intact or after conversions to 
other amino acids. Part of the absorbed amino acids remain in small intestine enterocytes to 
participate in local protein synthesis (house-keeping functions, apoproteins, digestive 
enzymes, hormones, nitrogen containing compounds). Glutamine for example is highly used 
for energy production in small intestine enterocytes. Amino acids released in the portal 
circulation are highly taken up by liver periportal hepatocytes (up to 50% after a meal) where 
they may be converted to other amino acids depending on the body’s requirements and/or 
released back into the circulation. Exceptions are glutamate and aspartate that are mostly 
taken up by perivenous hepatocytes and branched chain amino acids (valine, isoleucine and 
leucine) that are mostly taken up by muscle. Amino acids present in the circulation after a 
meal are quickly absorbed by the tissues leaving only a small pool of amino acids behind that 
mixes with the body’s protein degradation products ([total plasma amino acids] = 2.4 mM ≈ 
1.5 g / 3 L plasma). Despite this small amount, amino acid reabsorption by the kidneys is 
critical and reaches 95-99%. Once amino acids reach their target destination in the cells, 
they will either participate in protein synthesis or nitrogen containing compounds synthesis 
like glutathione, carnitine, creatine, carnosine and choline. 
 
Adaptation of the body’s amino acid requirements to the diet’s amino acid composition partly 
relies on the ability to synthesise new amino acids from existing substrates. A second crucial 
characteristic of a diet’s nutritive impact is the presence of essential amino acids (typically 
20%), i.e. amino acids that cannot be synthesised by the body (Table 1). The first step of 
amino acid conversion is either deamination or transamination. Deamination is the process of 
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removing the ammonia group from an amino acid either obtaining another amino acid or an 
α-keto acid (or carbon skeletton) using specialised enzymes (lyases, dehydratases, 
dehydrogenases). Transamination, on the other hand, refers to the transfer of the amino 
group of one amino acid to another one or to an α-keto acid through the action of 
transaminases. Glutamate and α-ketoglutarate readily donate or accept amino groups and 
thereby play an important role in amino acid metabolism. Amino acids that cannot be 
synthesised through the process of transamination are defined as essential, and have to be 
acquired through the diet. This classification is however flexible as some amino acids can be 
conditionally or acquired essential for infants and growing children, during organ failure, 
premature birth† or cirrhosis§ (Table 1). 
 
Essential Non-essential
Leucine Alanine 
Isoleucine Cysteine§†° 
Valine Glutamine 
Histidine Glycine 
Threonine Serine 
Methionine Threonine 
Tryptophan Asparagine 
Phenylalanine Aspartate 
Lysine Proline†° 
 Tyrosine§ 
 Arginine° 
 
Table 1. Essential and non-essential L-amino acids. Conditional essential amino acids during 
growth°, premature birth† or cirrhosis§. Modified from (Gropper et al, 2005). 
 
The toxic ammonia freed during deamination of amino acids will be converted to urea by 
integration in the urea cycle. Urea can then be transported to the blood and is mostly 
eliminated in the urine. This is also the case for ammonia acquired from the diet, or from 
bacterial degradation of amino acids. Ammonia in the portal circulation is usually taken up by 
uragenic periportal hepatocytes, unless when present in excessive amounts leading to 
uptake by perivenous hepatocytes and integration in glutamine synthesis. The situation is 
similar in non-uragenic peripheral tissues where ammonia associates to glutamate to 
produce glutamine that is then transported to liver or kidney for catabolism. 
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There are multiple fate possibilities for the α-keto acid left over from de- or trans-amination 
depending on the amino acid it originates from and on the body’s energetic state. All α-keto 
acids can be fully oxidized to provide energy, reaching up to 50% of the liver’s energetic 
needs. Besides oxidation, α-keto acids may lead to the synthesis of glucose, ketone bodies, 
cholesterol or fatty acids. 
Glucogenic amino acids can be catabolised to components of the citric acid cycle leading to 
glucose synthesis. This situation is favoured by high glucagon:insulin ratios or 
glucocorticoids (cortisol). Ketogenic amino acids are catabolised to acetyl-CoA or 
acetoacetate that can then be converted to ketone bodies (Table 2). This is favoured by diets 
insufficient in carbohydrates. Fatty acids may be synthesised from amino acids in case of 
energy excess and sufficient dietary protein and carbohydrate supply (Gropper et al, 2005). 
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Glucogenic Yielded intermediate Ketogenic 
Yielded 
intermediate 
Alanine 
Glycine 
Serine 
Cysteine 
Tryptophan 
Threonine* 
Pyruvate 
Leucine 
Tyrosine 
Phenylalanine
Acetoacetate 
    
Glutamate 
Histidine 
Arginine 
Proline 
Glutamine 
α-ketoglutarate
Lysine 
Isoleucine 
Leucine 
Tryptophan 
Threonine* 
Acetyl-CoA 
    
Valine 
Methionine 
Threonine 
Isoleucine 
Succinyl-CoA   
    
Aspartate 
Phenylalanine 
Tyrosine 
Fumarate   
    
Asparagine 
Aspartate Oxaloacetate   
 
Table 2. Glucogenic and ketogenic amino acids with respective yielded intermediates during 
glucose and ketone bodies synthesis, respectively. Exclusively glucogenic or ketogenic 
amino acids are indicated in bold. * Physiological contribution unclear. Modified from 
(Gropper et al, 2005). 
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4. Amino Acid Transport across Epithelia 
4.1 Epithelial Structure and Common Properties 
 
While it is necessary for the body to acquire nutrients from external sources, it is also 
important to protect and regulate the inside milieu. Performing both tasks is possible by the 
presence of the epithelium, a sheet of cells that line all of the body’s contact areas with the 
outside. The movement of solutes across this dynamic barrier is regulated and can follow two 
paths, the paracellular route (between the cells) and the transcellular route (through the 
cells). 
 
The paracellular route is controlled by an essential feature of the epithelium, the tight 
junctions or zona occludens. These protein complexes allow close association of two 
adjacent cells thereby increasing their adherence and restraining free diffusion of solutes. 
Indeed, tightness of an epithelium is proportional to the amount of tight junctions. Another 
important function of the tight junctions is to set a boundary between the apical membrane 
usually facing the outside, and the basolateral membrane facing the extracellular fluid. Such 
a barrier allows polarization of the cells by keeping the proteins and lipids in the membrane 
they have been sorted to. This allows distinct but complementary membrane functions and 
vectorial transport against concentration and/or electrical gradients. For example, the Na/K-
ATPase is almost always restricted to the basolateral membrane. Other junctional complexes 
include adhering junctions (zona adherens, allowing cell-to-cell contact), gap junctions 
(cytosol connection) and desmosomes (macula adherens, for structural stabilisation) (Figure 
2). Structural support and help in architectural organisation is given by the basement 
membrane which is secreted by the basolateral membrane. It consists of extracellular matrix 
proteins (collagen, laminin, proteoglycans,…) and informs the cell on orientation. 
 
Passage of polar molecules through the transcellular route is protected by the hydrophobic 
interior of the lipid bilayer in the cell membrane. Transcellular movement of water-soluble 
organic molecules therefore requires the presence of specific transport proteins. The 
expression of these transport proteins depends on the function of the organ delimited by the 
epithelium, but protein expression pattern is also heterogeneous within each organ, it can 
vary along the proximal-distal tubule axis in kidney as well as on the villus-crypt axis in the 
small intestine. 
 
In epithelial cells, many transport proteins and enzymes localize to the membrane. For 
efficient transport, the apical membrane surface is often amplified (up to 20 times) by 
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microvillar projections that constitute the brush border. The basolateral membrane may also 
have lateral interdigitations and basal infoldings, though to a smaller extent than on the 
apical side (Boron & Boulpaep, 2005). 
 
 
 
Figure 2. Epithelial cell scheme. Source : http://mednote.co.kr/images/membr-junction.jpg 
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4.2 Intestinal Absorption 
4.2.1 Organisation of the Gastrointestinal Tract 
 
The gastrointestinal tract is composed of a tube of hollow organs stretching from the mouth 
to the anus, complemented by organs adding secretions. The hollow organs are separated 
by sphincters, allowing specialisation and the sequential processing of food (Figure 3). Food 
is first chopped in small pieces and lubricated in the mouth and oropharynx, where 
carbohydrate and fat digestion begins. Ingested food is then propelled to the stomach 
through the oesophagus. Gastric content is then transferred to the small intestine where 
digestion continues and nutrient absorption primarily occurs. Fluid and electrolyte absorption 
and secretion take place in the small as well as in the large intestine which additionally 
serves as storage of fecal matter. 
 
The wall of the gastrointestinal tract is organised in a mucosa, a submucosa, a muscle layer 
and a serosa. The mucosa is constituted of an epithelial cell layer and loose connective 
tissue (lamina propria), as well as capillaries, enteric neurons, immune cells and a thin layer 
of smooth muscle (lamina muscularis mucosae). The small intestine epithelial cell layer is 
organised in evaginated villi where the absorption of nutrients and electrolytes takes place, 
and invaginated crypts of Lieberkühn that are responsible for secretion (Figure 3). This 
structure is additionally organised in folds of Kerckring, increasing the absorptive surface to a 
total of 200 m2 in the small intestine. The submucosa consists of loose connective tissue, 
larger blood vessels and glands. There are two muscle layers (muscularis externa) 
surrounding these structures, a circular and a longitudinal one which generate the peristaltic 
movement and receive the enteric neuron projections. The serosa, an envelope of 
connective tissue covered by squamous epithelial cells finally covers the whole tract. 
 
The small intestine is a dynamic organ with proliferation of epithelial cells at the base of the 
crypt which then migrate towards the tip of the villus. The progenitor or stem cell 
differentiates to a vacuolated cell, a goblet cell, a Paneth cell or an enteroendocrine cell. 
Vacuolated cells then differentiate to villous absorptive cells that migrate to the tip of the 
villus and slough in the lumen over a 48-96 hours cycle, depending on the fasting/feeding 
state. Goblet cells secrete mucus, Paneth cells provide host defense against bacteria or 
bacterial antigens, and enteroendocrine cells sense the luminal environment and secrete 
hormones on the blood side. There the hormones modulate intestinal motility, augment 
pancreatic β-cell response or induce satiety (gastrin, cholecystokinin, glucose-like peptide 1, 
Peptide YY) (Cummings & Overduin, 2007).  
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Function of the gastrointestinal tract is regulated by the enteric nervous system (ENS) with 
sensory neurons, interneurons and secretomotorneurons (total of 100 million neurons). The 
ENS constitutes in itself a complete reflex circuit stimulating or inhibiting smooth muscle 
cells, epithelial cells, enteroendocrine cells and submucosal vessels. The ENS is additionally 
under the control of the autonomic nervous system, hormones as well as the immune system 
(Boron & Boulpaep, 2005). 
 
 
                    
 
Figure 3. Gastrointestinal tract and intestinal section scheme (Gray, 1918). 
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4.2.2 Protein Digestion 
 
Digestion is the process of converting complex dietary substances to absorbable molecules. 
It occurs through mechanical and chemical processing. 
To be absorbed, proteins are enzymatically digested to free amino acids or di- and tri-
peptides by gastric proteases in the stomach and by pancreatic enzymes and brush border 
dipeptidases in the small intestine. Inside the enterocytes, di- and tri-peptides are hydrolysed 
to single amino acids by cytosolic enzymes. Amino acids are then released in the portal 
circulation. Protein digestion and uptake of amino acids is a very effective process with less 
than 4% of ingested nitrogen going in stool. There is only an antigenic amount of protein that 
is absorbed intact in the small intestine, except in neonates where it plays an important role 
for dietary protein immune response. 
There are 70 to 100 g of protein ingested every day, which is complemented by the digestion 
of endogenously secreted proteins. This means that half of the proteins entering the small 
intestine are enzymes, hormones, and immunoglobulins from salivary, gastric, pancreatic, 
biliary and jejunal secretions (17 g / day), as well as desquamated epithelial cells (50 g / 
day). Protein digestion is influenced by the amino acid composition (proline-rich is less 
digested), the source of the diet (vegetal less digested), and food processing (cooking, 
storage). 
 
Chemical digestion of proteins starts in the stomach where HCl is secreted by the gastric 
parietal cells in response to various stimulations (gastrin, acetylcholine, histamine), and will 
denature quaternary, tertiary and secondary structures without affecting peptide bonds. 
Gastric and pancreatic enzymes are usually converted from a proenzyme to an active 
enzyme form to avoid auto-digestion processes. The proenzyme pepsinogen secreted by 
gastric chief cells is converted to pepsin by HCl, as well as by the newly formed pepsin 
(positive feedback mechanism). Pepsin is a low specificity endopeptidase digesting 10-15% 
of proteins with high activity at pH < 3.5, generating large polypeptides, oligopeptide and free 
amino acids. The stomach content is then delivered to the small intestine through the pylorus 
where it will stimulate the secretion of regulatory hormones/peptides such as secretins like 
cholecystokinine (CCK) from mucosal enteroendocrine cells into the blood (Cummings, 
Overduin). These secretins reach the pancreas and acinar cells which then secrete alkaline 
pancreatic juice, electrolytes, water and digestive proenzymes/zymogens. 
Intestinal brush border enzymes convert the proenzyme trypsinogen to trypsin, that in turn 
converts chymotrysinogen to chymotrypsin, and the procarboxypeptidases to 
carboxypeptidases. Brush border peptidases cleave 3-8 amino acids oligopeptides, acting as 
endo- or exo-peptidases from the C or  the N terminus (Table 3) (Boron & Boulpaep, 2005; 
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Gropper et al, 2005). The relatively fewer cytosolic peptidases cleave specific bonds in 2-3 
amino acids peptides. 
Amino acids are finally taken up by the enterocytes either in the form of di- and tri-peptides 
by the proton coupled peptide transporter (PepT1, Slc15a1), or in the form of free amino 
acids by amino acid transporters (see section 5). 
 
Proenzyme 
production site Enzyme Activity site 
Substrate (peptide bonds 
adjacent to) 
    
Stomach Pepsin Endopeptidase Most AA1 
    
Trypsin Basic AA 
Chymotrypsin Aromatic AA 
Elastase 
Endopeptidases
 
   
Carboxypeptidase 
A 
Cter2 Neutral AA 
Pancreas 
Carboxypeptidase 
B 
Exopeptidases 
Cter Basic AA 
    
Aminopeptidases 
Dipeptidylpeptidase 
Brush border 
Tripeptidylpeptidase
Exopeptidases Nter3 
 
Table 3. Overview and mode of action of some digestive enzymes. 1AA: amino acids. 2Cter: 
carboxy terminal. 3Nter: amino terminal. Modified from (Gropper et al, 2005). 
 
 
4.3 Kidney Reabsorption 
 
4.3.1 Anatomy and Physiology of the Kidney 
 
The kidney is a paired, bean-shaped organ of 115-170 g in human that filters toxins and 
metabolic products, assures homeostasis of acids and bases, electrolytes and water and 
also produces hormones for erythrogenesis, calcium metabolism, regulation of blood 
pressure and blood flow.  
An opening called the hilus is the entry point for the renal artery and nerves and the exit point 
for the renal vein and the lymphatic system. Macroscopic kidney structure, from inside to 
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outside, is arranged in renal sinus, medulla and cortex. The renal sinus collects urine formed 
from the glomerular filtrate by the nephron, directing it to the bladder for storage. In the 
medulla, tubules are arranged in parallel and organised in 8-18 conically shaped pyramids, 
whereas in the cortex the tubules are organised in convoluted structures (Figure 4).  
 
The functional unit of the kidney is the nephron (800’000 to 1’200’000 in human and 100’000 
in mouse) which consists of the glomerulus and the tubule. The glomerulus is a cluster of 
blood vessels that form the filtrate. The tubule is an epithelial structure that through the 
action of specialised subdivisions forms urine from the glomerular filtrate. These two 
structures join at Bowman’s capsule, which is contiguous to the tubule lumen. 
Nephrons are organised in two categories depending on glomerulus localisation and 
extension of the loop of Henle. Glomeruli of superficial nephrons are in the cortex and the 
loop of Henle only extends till the outer and inner medulla, while juxtamedullary nephrons 
have their glomeruli at the limit between cortex and medulla, with the loop of Henle reaching 
until the tip of the medulla. 
 
The renal corpuscule is where blood is filtered from the capillary network to the Bowman 
space in the Bowman capsule. The glomerular filtration barrier consists of endothelial cells 
forming fenestrated capillaries surrounded by the glomerular basement membrane and 
epithelial podocytes, with the exception of the center where endothelial cells are in direct 
contact with the mesengial cells. 
A first filtration occurs through the 70 nm fenestrations that only restrict cellular elements. 
The basement membrane consists of 3 layers and restricts the passage of medium to large 
solutes (> 1 kDa) and additionally possesses a strong anionic charge. The podocyte foot 
processes are separated by filtration slits that are covered by a thin structure, the slit 
diaphragm, with 4 to 14 nm diameter pores. A network of contractile mesangial cells in the 
capsule supports the structure by secreting an extracellular matrix. 
 
Even though kidneys only represent about 0.5% of the total body weight, they receive up to 
20% of the cardiac output. The vascular elements of the renal circulation are a high-
resistance afferent arteriole, a high-pressure glomerular capillary network, a high-resistance 
efferent arteriole and a low pressure capillary network that surrounds the tubules and takes 
up the reabsorbed fluid.  
Pressure in the afferent and efferent arterioles determine the hydrostatic pressure in the 
glomerular capillaries. The arteriole tone is controlled by sympathetic innervation and 
chemical mediators, and there is no parasympathetic innervation in the kidney. Blood flow in 
the cortex comes from efferent arterioles of superficial glomeruli, receiving 90% of renal 
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artery blood, while blood flow in the medulla originates from juxtamedullary glomeruli efferent 
arterioles that form the vasa recta and receives the remaining 10% blood supply. Lymph 
vessels drain interstitial fluid of the cortex and contain high levels of hormones (e.g. renin), 
but not the one of the medulla which would otherwise wash the osmotic gradient away. 
 
The juxtaglomerular apparatus (JGA) is an important structure that regulates renal blood 
flow, filtration rate, Na+ balance and systemic blood pressure. It is composed of an 
extraglomerular matrix, the macula densa cells and the granular cells. The macula densa 
cells are specialised cells of the thick ascending limb that contact the glomerulus. The 
granular cells, or juxtaglomerular cells, are specialized smooth muscle cells from the afferent 
arteriole that produce, store and release renin (see section 6.1). The JGA also allows 
tubuloglomerular feedback which induces the decrease of glomerular filtration rate upon 
increases of fluid or NaCl concentration at the macula densa. 
 
Tubule function relies on its highly specialised segments that contain specialised 
transporters. The proximal tubule is divided in convoluted segments S1 and S2 (PCT: 
proximal convoluted tubule) and the straight segment S3 (PST: proximal straight tubule). The 
richly folded brush border membrane of this segment allows high reabsorption rates of 
nutrients (amino acids, glucose), NaCl, NaHCO3, water, and divalent ions (PO42-, Ca2+, SO42-
), as well as secretion of NH4+ and many other solutes. 
This segment is followed by the loop of Henle that ends at the macula densa. Its role is to 
concentrate or dilute urine. For this purpose, a hyperosmotic interstitium gradient is 
generated in the medulla by the juxtamedullary nephrons. This gradient may or may not be 
used to concentrate urine in the distal medullary collecting ducts depending on the body’s 
requirements. 
The distal tubule and the collecting duct system are responsible for the fine control of water 
and salt excretion. The distal convoluted tubule (DCT) starts at the macula densa and is 
followed by the connecting tubule (CNT) and the cortical collecting ducts (CCD). CNT and 
CDs are composed of two cell populations, the principal cells and the intercalated cells that 
are further separated in distinct populations (α and β). Different collecting ducts branches join 
to form  the cortical collecting tubule (CCT) which are divided to outer and inner medullary 
CD (OMCD and IMCD, respectively) with only one cell type present (Boron & Boulpaep, 
2005). 
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Figure 4. Nephron structure (Boron & Boulpaep, 2005). 
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5. Amino acid transporters 
5.1 Membrane Transport of Small Molecules 
 
As mentioned earlier, the transcellular transport of small water-soluble molecules like ions, 
sugars and amino acids is limited by the hydrophobic lipid bilayer of the membrane. Specific 
sets of transport proteins allow uptake and efflux of these solutes to occur. 
Membrane transport proteins are typically classified in pores, carriers and channels. Pores 
are always open structures (e.g. aquaporin). Carriers are never fully open and undergo 
conformational changes upon binding of a solute to a carrier on one side of the membrane 
that leads to the release of the solute on the other side of the membrane (e.g. amino acid 
transporters, glucose transporters). This is in contrast to channels that are alternatively open 
and closed. Though they have weaker interactions with the solutes, they form aqueous pores 
in the open conformation (e.g. ion channels). The formation of a pore implies that the rate of 
transport of channels is much faster than that of carriers. 
 
Channels only mediate the passive transport of solutes, in contrast to carriers that may 
mediate passive transport (or facilitated diffusion). In that case, the solute follows its 
electrochemical gradient. Carriers may mediate passive or active transport, the latter being 
coupled to an energy source.  
Carrier mediated solute transport is similar to an enzyme-substrate reaction. The carrier can 
be saturated up to a maximum transport rate Vmax, which depends on the speed of the 
conformation change. Each solute also has a specific binding affinity to the carrier (Km) that is 
the concentration of solute when the transport is half of Vmax. 
Carriers may be uniporters if only a single solute is transported, or coupled transporters if 
more than one solute is transported. The transporter is then described as a symporter when 
the coupled transport is in the same direction or as an antiporter when solutes move in 
opposite directions. 
The energy necessary for active transport against an electrochemical gradient in animal cells 
may directly or indirectly come from ATP hydrolysis leading to the classification of primary, 
secondary or tertiary active transporters. In primary active transport solute movement against 
its electrochemical gradient is associated to the hydrolysis of ATP. Secondary active 
transport by a coupled transporter uses the gradient generated by the primary active 
transport and couples it to a solute’s movement against an electrochemical gradient. Tertiary 
active transport functions similarly. For example, the Na/K-ATPase is a primary active 
transporter that extrudes Na+ and imports K+ against their electrochemical gradients and that 
is fuelled by ATP hydrolysis. Na+ is then prone to enter the cells coupling its transport to, for 
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example,  dicarboxylates via the secondary active Na+ dicarboxylate transporter NaDC1. The 
generated dicarboxylate gradient can then be used by the tertiary active dicarboxylate / 
organic anion transporter (OAT1) to import organic anions inside the cells (Alberts et al, 
2002; Boron & Boulpaep, 2005). 
 
 
5.2 Amino Acid Transporters 
 
In 1913, Van Slyke and Meyer showed that amino acids are absorbed from the blood to the 
tissues against a concentration gradient by infusing digested casein in the blood of dogs 
resulting in 5-10 times more amino nitrogen in the tissues than in blood (Van Slyke & Meyer, 
1913). In the 1960s, amino acid transport was investigated in erythrocytes, hepatocytes 
(Kilberg et al, 1980), fibroblasts and other cell types (Christensen & Oxender, 1960) and 
classified in systems. These systems transport amino acids depending on their physico-
chemical properties, stereospecificity, size and charge. Further characterisation of the 
systems included Na+ and pH dependency, inhibition by synthetic amino acids, and showed 
that some systems had overlapping functions (Christensen, 1989). 
An attempt to simplify the nomenclature was suggested in 1984. The guideline was to use 
roman letters that would not evoke a single amino acid since these systems usually transport 
multiple amino acids. The symbols y+, x- and 0 were proposed for basic, acidic and 
zwitterionic amino acid transporter systems with the possibility to add subscript letters to 
indicate specificity (though it does not follow the single letter code for acidic amino acid 
systems A: asparate, G: glutamate, C: cystine). Na+ dependency is usually indicated by 
capitalisation though the previously characterised Na+-independent system L (referring to its 
preferred amino acid leucine) was not retroactively modified (Bannai et al, 1984; Oxender & 
Christensen, 1963). 
Genetic identification of the molecular correspondents of amino acid transport systems 
began in the early 90’s (Broer, 2008; Kanai & Hediger, 1992; Kavanaugh et al, 1994; Palacin 
et al, 1998; Verrey et al, 1999) and usually followed the systems nomenclature with the 
addition of AT for amino acid transporter, as well as a number for different variants sharing a 
same transport system (e.g. system L: LAT1, LAT2, …). This allowed functional 
characterisation of the transporters in cells or in the Xenopus laevis oocytes heterologous 
system, the measurement of mRNA expression levels in tissues and the production of 
antibodies for localisation studies. Further investigations of the transporters’ physiological 
impact in vivo were investigated in knock-out mouse models (Peters et al, 2003; Quan et al, 
2004; Singer et al, submitted; Sperandeo et al, 2007; Stoffel et al, 2004; Tsumura et al, 
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2003). An overview of the different amino acid transporters and corresponding systems is 
displayed in table 4. 
 
Transport 
system 
Transporters 
(associated 
with) 
Other 
names Gene Mechanism 
Physiological 
substrates1 
      
SNAT1 ATA1, GlnT, 
SAT1, NAT2, 
SA2 
SLC38A1 G, A, S, C, Q, 
N, H, M 
SNAT2 ATA2, SA1, 
SAT2 
SLC38A2 G, P, A, S, C, 
Q, N, H, M 
System A 
SNAT4 ATA3, NAT3, 
PAAT, SAT3 
SLC38A4 
1Na+/AA2 
cotransport 
G, P, A, S, C, 
N, M 
      
Asc1 
(4F2hc) 
- SLC7A10 Small neutral 
D and L-AA 
System asc 
Asc2 
(?hc) 
- SLC7A- 
antiporter 
G, A, S, T 
      
ASCT1 SAAT1 SLC1A4 A, S, C System ASC 
ASCT2 ATB0 SLC1A5 
Na+-dependent 
Or antiporter A, S, C, T, Q 
      
System b0,+ b0,+AT 
(rBAT) 
NBAT/lc6 SLC7A9 antiporter Cationic and 
large neutral AA 
      
B0AT1 
(Tmem27/ACE
2) 
XT2s1 SLC6A19 Broad range neutral 
AA 
B0AT2 NTT v3-7 SLC6A15 P, Large neutral AA 
System B0 
B0AT3 
(Tmem27) 
XT2 SLC6A18 
Na+/AA 
cotransport 
Broad range neutral 
      
System B0,+ ATB0,+ - SLC6A14 2Na+/1Cl-/AA 
cotransport 
Neutral and cationic 
AA 
      
GAT1 - SLC6A1 Na+/Cl-/AA 
cotransport 
GABA 
GAT2 BGT1 SLC6A12  GABA, betaine 
System β 
GAT3 GAT2 SLC6A13  GABA 
 GAT4 GAT3 SLC6A11  GABA 
      
System Gly GlyT1 - SLC6A9 2-3Na+/1Cl-/AA 
cotransport 
G 
 GlyT2 - SLC6A5  G 
      
Imino acid 
carrier 
PAT1 LYAAT1 SLC36A1 1H+/AA 
cotransport 
P, G, A, β-Ala, 
GABA 
 PAT2 Tramdorin1 SLC36A2  P, G, A 
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Transport 
system 
Transporters 
(associated 
with) 
Other 
names Gene Mechanism 
Physiological 
substrates1 
      
System 
IMINO 
SIT1 
(Coll/ACE2) 
XT3s1, XT3 SLC6A20 Na+/Cl-/AA 
cotransport 
Imino acids 
      
LAT1 
(4F2hc) 
- SLC7A5 Large neutral AA 
LAT2 
(4F2hc) 
4F2hc-lc5 SLC7A8 
antiporter 
Neutral AA 
LAT3 - SLC43A1 Neutral AA 
System L 
LAT4 - SLC43A2 
uniport 
Neutral AA 
      
SNAT3 NAT1, 
SN1 
SLC38A3 Q, N, H System N 
 
SNAT5 SN2 SLC38A5 
Na+/AA 
cotransport/H+- 
antiport Q, N, H, S, G 
      
System T TAT1 MCT10 SLC16A10 uniport F, Y, W 
      
EAAT1 GLAST SLC1A3 E, D 
EAAT2 GLT-1 SLC1A2 E, D 
EAAT3 EAAC1 SLC1A1 E, D, C 
EAAT4 - SLC1A6 E, D 
System XAG 
 
EAAT5 - SLC1A7 
3Na+/1H+/AA 
cotransport/1K+
- 
antiport 
E, D 
      
System x-c xCT 
(4F2hc) 
- SLC7A11 antiporter E, C- (no D) 
      
CAT-1 ATRC1 SLC7A1 uniporter R, K, H 
CAT-2A/B ATRC2, 
TEA 
SLC7A2 R, K, H 
CAT-3 ATRC3 SLC7A3 R, K 
System y+ 
(CAT-4) - SLC7A4 
? 
? 
      
y+LAT1 
(4F2hc) 
- SLC7A7 K, R, Q, H, M, 
L 
System y+L 
y+LAT2   
(4F2hc) 
- SLC7A6 
Na+-dependent 
antiporter 
K, R, Q, H, M, 
L, A, C 
 
Table 4. Overview of amino acid transporter systems, corresponding proteins, genes and 
substrates. 1Amino acids are given in the one-letter code (C- Cystine), weak substrates are 
shown in parenthesis. 2AA: amino acids. Adapted from (Broer, 2008). 
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5.3 The SLC6 family 
 
Transporters or Solute Carriers (SLC) of the human genome are organised in 43 families 
with 20-25% of amino acid sequence identity within a family (Hediger et al, 2004). 
The sodium- and chloride-dependent neurotransmitter and amino acid transporter family 
SLC6 is, with 20 members, the largest solute carrier family of transporters. SLC6 members 
code for proteins of approximately 600 amino acids with 12 transmembrane segments and 
intracellular N- and C- termini (Nelson, 1998). A specific feature of this family is a large 
extracellular loop between transmembrane segments 3 and 4. It has also been shown that 
some members may form homo-oligomers. Transport of solutes against the electrochemical 
gradient is driven by Na+ co-transport with the number of co-transported Na+ varying from 1 
to 3. In many cases, the co-transport of Cl- also occurs (Broer, 2006; Chen et al, 2004). 
 
The phylogenetic tree of this family evidences four distinct branches (Figure 5): 
- The GABA transporter branch with the γ-aminobutyric acid (GABA) transporter 1 (GAT1, 
Slc6a1), the first member to be identified and extensively characterised. This cluster also 
contains the creatine transporter 1 (CT1, Slc6a8) and the taurine transporter (TauT, 
Slc6a6). 
- The monoamine transporter branch with the dopamine (DAT, Slc6a3), the serotonin 
(5HTT, Slc6a4) and the norepinephrine (NET, Slc6a2) transporters. 
- An amino acid branch, containing β-alanine, neutral and cationic amino acid transporter 
ATB0,+ (Slc6a14) as well as glycine (GlyT1/2, Slc6a9/5) and proline transporters (ProT, 
Slc6a7) predominantly expressed in brain (Eulenburg et al, 2005). 
- The transporters of the second branch of amino acids, previously known as the “orphan 
transporters” branch will be described further in sections 5.3.1-5.3.3. They have been 
shown to localise on the apical membrane of kidney proximal tubule, and in some cases 
small intestine. Correct localisation at the membrane is dependent on co-expression of 
tissue specific associated proteins Tmem27 in the kidney and homolog ACE2 in the small 
intestine (see section 6.2.1-6.2.2) (Camargo et al, in press; Danilczyk et al, 2006; 
Malakauskas et al, 2007; Singer et al, submitted). 
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Figure 5.  Phylogenetic tree of the mouse SLC6 family (Romeo et al, 2006). 
 
 
5.3.1 B0AT1 (Slc6a19) 
 
Transport of large neutral amino acids in kidney and in small intestine was first described to 
be controlled by system B0 (Doyle & McGivan, 1992a; Doyle & McGivan, 1992b). Evidence of 
B0AT1 transporter involvement came through the characterisation of the autosomal recessive 
Hartnup disorder. This disorder is characterized by neutral aminoaciduria due to impaired 
amino acid transport in kidney proximal tubule whereas the extent of intestinal transport 
impairment appears to be less consistent. Various other clinical symptoms such as pellagra-
like rash, cerebellar ataxia and other neurological dysfunctions may be present in affected 
individuals, while other subjects remain asymptomatic besides aminoaciduria (Baron et al, 
1956). Phenotypic variability might be partially explained by the differential impact of various 
mutations and the frequent compound heterozygosity. Little was known about the cause of 
the disorder but its link to chromosome 5p15 in human (Nozaki et al, 2001). Screening for 
genes encoding proteins with more than 5 transmembrane domains typical of the SLC 
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members identified genes Slc6a18 (B0AT3) and Slc6a19 (B0AT1). In mouse, the slc6a19 
gene localises to chromosome 13 in cytoband C1. It has 12 exons encoding a 634 amino 
acids protein (Bohmer et al, 2005; Camargo et al, 2005).  
Expression of mouse Slc6a19 in the Xenopus laevis oocytes heterologous system induced 
electrogenic transport of a broad range of neutral amino acids. In that system, B0AT1 has a 
low affinity constant for L-leucine (K0.5 = 1.16 mM) (Bohmer et al, 2005; Camargo et al, 
2005). Additionally, B0AT1 substrate-induced currents are Na+-dependent and Cl-- and H+-
sensitive. In accordance with the in vitro data, B0AT1 localises to the brush border membrane 
on the apical side of villi enterocytes in the small intestine and early proximal tubule cells (S1, 
S2) in the kidney (Romeo et al, 2006). Proximal tubule reabsorption of solutes often displays 
axial gradient of distribution of a low affinity component in the early segments (S1) and a 
higher affinity component in the later segments (S3). Accordingly, glucose and peptide 
transporters SGLT2 (Slc5a2) and PepT1 (Slc15a1) in S1 have a complementary distribution 
to that of SGLT1 (Slc5a1) and PepT2 (Slc15a2). For neutral amino acids, B0AT1 probably 
corresponds to the low affinity component, while B0AT3 (see section 5.3.2) corresponds to 
the high affinity component (Anderson et al, 2004; Boll et al, 2004; Daniel et al, 2006). 
In contrast to mouse B0AT1, X. laevis oocytes expressing human B0AT1 only accumulated 
little amounts of radiolabeled amino acids, and the current generated by the co-transport of 
Na+ and amino acid were too small to characterise (~ 10 nA). This suggested that correct 
expression of the human B0AT1 at the plasma membrane required co-expression of an 
associated protein. The work presented in this thesis reports the organ specific association of  
B0AT1 with Tmem27 in the kidney and ACE2 in the small intestine (Camargo et al, in press; 
Danilczyk et al, 2006; Malakauskas et al, 2007) (see sections 6.1.2 and 6.1.3). Indeed, co-
expression of the associated proteins in oocytes confirmed human B0AT1 functional 
correspondence to the mouse ortholog. The relationship between Hartnup disorder and 
B0AT1 was confirmed when most cases of the disorder were shown to be caused by 
mutations in B0AT1 (Kleta et al, 2004). We also showed that Hartnup disorder-causing 
mutations differentially interact with the associated proteins, thereby participating in 
phenotypic heterogeneity (Camargo et al, in press). 
 
 
 
27 
5.3.2 B0AT3 / XT2 (Slc6a18) 
 
The B0AT3 gene Slc6a18, previously known as orphan transporter XT2, is arranged in 
tandem with that of B0AT1 (Slc6a19) on chromosome 5 in human and 13 in mouse (Nash et 
al, 1998). These genes share 52% sequence identity and thus presumably arose by gene 
duplication (Romeo et al, 2006). Mouse Slc6a18 was identified by screening a genomic 
library with a rat dopamine transporter-derived probe with a highly conserved motif. Slc6a18 
is constituted of 13 exons with alternative splicing and a splice acceptor, resulting in 6 
transcribed isoforms. The A12 isoform is however the only one with 12 putative 
transmembrane segments, in accordance with the SLC6 family members organisation. The 
physiological significance of the five shorter transcripts has until now not been established 
(Nash et al, 1998). 
The rat ortholog of Slc6a18 is a renal osmotic stress-induced transcript (ROSIT) which was 
first identified as an upregulated transcript in hypertonic renal cortex (Wasserman et al, 
1994). However, study of mouse B0AT3 in osmotic stress conditions did not verify such a 
regulation (Elisa Romeo and François Verrey, unpublished data). Already then, the function 
of ROSIT, and later of mouse Slc6a18 (94.6% identity) was tested in X. laevis oocytes 
without success (Nash et al, 1998; Quan et al, 2004; Wasserman et al, 1994). Direct function 
of B0AT3 eluded demonstration for 10 years, until co-expression with associated protein 
ACE2, but not Tmem27, in X. laevis oocytes made characterisation possible. As 
hypothesised based on its high identity to B0AT1, B0AT3 transports a broad range of neutral 
amino acid (A, M, V, I > G, S, L). Further characterisation showed that L-isoleucine is 
transported with high affinity (K0.5 = 0.21 mM) in a Na+ and Cl- dependant as well as pH-
independent manner (Singer et al, submitted). In contrast to the association with ACE2 
observed in Xenopus laevis oocytes, experiments with ace2 and tmem27 null mice 
demonstrate that in vivo it is Tmem27, a smaller homologue of ACE2, which is required for 
functional expression of B0AT3 in kidney (Danilczyk et al, 2006; Malakauskas et al, 2007; 
Singer et al, submitted).  
Localisation studies performed in mouse tissues have shown that B0AT3 is highly expressed 
in kidney, where it localises to the brush border membrane of the late proximal tubule (S2, 
S3), in a complementary fashion to B0AT1 that localises to the early proximal tubule (S1) 
(Romeo et al, 2006). As previously mentioned, B0AT3 corresponds to the high affinity 
component of neutral amino acid transport. 
An Slc6a18 null mouse model was first generated and analyzed by the group of Marc Caron. 
The high amounts of glycine found in the urine of these mice supported the hypothesis that 
the orphan gene product B0AT3 functioned as an amino acid transporter. Brush border 
membrane vesicles uptake additionally evidenced its function as a high affinity transport 
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system of glycine (Quan et al, 2004). The work presented in this thesis re-analysed the 
B0AT3 knock-out mouse model after more than 10 generations of backcrossing into C57BL/6 
background. Next to the previously published glycinuria, a urinary loss of several other amino 
acids, in particular beta-branched and small neutral ones was observed. 
Surprisingly, the Slc6a18 null mice displayed a systolic blood pressure that was 15 - 20 
mmHg higher than that of their wild-type litter mates, a difference that was abolished upon 
glycine supplementation in drinking water. Using telemetry, the previously described link of 
B0AT3 lack and hypertension was confirmed, but only in physically restrained animals 
(Singer et al, submitted). Such an impact of B0AT3 on blood pressure was not confirmed in 
human where a SNP within the SLC6A18 gene present in 46.7% of a general Japanese 
population corresponds to a nonsense mutation (Y319X) and is not associated with 
hypertension (Eslami et al, 2006). 
 
 
5.3.3 SIT1 / XT3s1 / XT3 (Slc6a20) 
 
The human sodium / imino-acid transporter SIT1 (XT3, Slc6a20) corresponds to system 
IMINO, mediating proline transport and escaping alanine inhibition (Stevens & Wright, 1985; 
Stevens & Wright, 1987). This gene localises to chromosome 3p21.3, is transcribed to a 592 
amino acids protein and is expressed in small intestine epithelium and kidney (Takanaga et 
al, 2005). An additional 555 amino acids form that arises following the deletion of a 
transmembrane segment by alternative splicing is present in brain (Kiss et al, 2001). 
Nomenclature in mouse may lead to possible confusions as there are two closely related but 
distinct genes on chromosome 9F4 (90% identity), Slc6a20a (“similar to XT3” XT3s1) and 
Slc6a20b (XT3). Characterisation of murine Slc6a20 variants in X. laevis oocytes showed 
that XT3s1/SIT1 corresponds to SIT1, whereas orphan XT3 expression alone did not lead to 
any uptake of the tested amino acid substrates (Kowalczuk et al, 2005). XT3s1 has been 
found to localise to the brush border of mouse kidney proximal tubule and small intestine 
enterocytes, and also has a broad tissue expression (brain (cerebellum, cortex, brain stem), 
thymus, spleen and lung) (Romeo et al, 2006; Takanaga et al, 2005). XT3 is only found 
expressed in kidney with a localisation similar to that of XT3s1 (Romeo et al, 2006). Similarly 
to B0AT1, expression of XT3s1 may be controlled by the associated proteins Tmem27 in the 
kidney and possibly ACE2 in the small intestine (Danilczyk et al, 2006). 
Study of human and mouse SIT1 showed high affinity uptakes of L-proline (Km = 0.17 mM 
and 0.13 mM respectively), MeAIB and betaine, typical of IMINO system. Additionally, 
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susbtrate transport is electrogenic and displays Na+ and Cl- dependence with a stoichiometry 
of 1:2:1 (Kowalczuk et al, 2005; Takanaga et al, 2005). 
Other entry routes for L-proline include the imino acid carrier PAT1 that additionally 
transports glycine as well as B0AT1 (Anderson et al, 2004; Boll et al, 2004; Camargo et al, 
2005; Munck et al, 1994; Roigaard-Petersen et al, 1987). 
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6. Regulation of Blood Pressure 
 
6.1 General 
 
The regulation of blood pressure on a short and long term time scale is necessary to 
appropriately perfuse organs in response to the different demands of everyday life. 
Short term regulation mainly consists of a neural reflex composed of a series of negative 
feedback loops with stretch receptors or mechanoreceptors in the carotid sinus and the aortic 
arch serving as detectors of blood pressure variation. These variations are then transduced 
to an electrical signal which is transmitted to the coordinating centre in the central nervous 
system through afferent neural pathways. Most of the information is processed in the nucleus 
tractus solitarius in the medulla oblongata with excitatory projections to the cardioinhibitory 
area or inhibitory projections to the vasomotor area. Sympathetic and parasympathetic 
efferent neural pathways to effectors in the heart (pacemaker cells and muscle cells), the 
veins (vascular smooth muscle cells, VSMCs) and the adrenal medulla (chromaffin cells) 
accordingly regulate blood pressure. 
Long term control of blood pressure (hours – days) is modulated by the humoral control of 
vessels and kidney function either affecting cardiovascular and VSMCs (vasoactive) or 
control of extracellular fluid volume (ECF, non-vasoactive). Vasoactive effectors include 
angiotensin II (Ang II), bradykinin, epinephrine, serotonin, and histamine. Non-vasoactive 
effectors control ECF volume through Na+ balance control. As no sensor measures a volume, 
the fullness of the system can be sensed through several pathways: the previously 
mentioned high and low pressure sensors of the autonomic nervous system, the renin 
angiotensin aldosterone system (RAAS, see section 6.1), the atrial myocytes secreting the 
atrial natriuretic peptide (ANP) and the osmoreceptors in the central nervous system that 
stimulate thirst and release of the antidiuretic hormone arginine vasopressin (AVP) by the 
posterior pituitary (Figure 6) (Boron & Boulpaep, 2005). 
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Figure 6. Feedback control of effective circulating volume. A low effective circulating volume 
triggers four parallel effector pathways that act on the kidney, either by changing 
hemodynamics or by changing Na+ transport by the renal tubule. ANS: autonomic nervous 
system. GFR: glomerular filtration rate (Boron & Boulpaep, 2005). 
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6.2 The Renin Angiotensin Aldosterone System 
 
The renin angiotensin aldosterone system (RAAS) controls blood pressure through the 
release of angiotensin II (Ang II). Renin is first released by the granular cells of the 
juxtaglomerular apparatus in the kidney in reponse to low effective circulating volume. This 
can be sensed by different systems:  sympathetic stimulation following a decrease in 
systemic blood pressure, decrease in NaCl concentration at the macula densa, decrease in 
renal perfusion pressure or decrease in the input to the stretch receptors of the granular 
cells. 
Renin release in the circulation cleaves the decapeptide precursor angiotensinogen 
synthesised and released by the liver to the octapeptide Ang I. Ang I is converted by the 
dipeptidyl carboxypeptidase angiotensin-converting enzyme (ACE) to Ang II, the main 
effector peptide of the RAAS. Ang II displays potent vasoconstrictive, pro-inflammatory, and 
pro-fibrotic properties. The majority of the cardiac and renal actions of Ang II, including 
vascular smooth muscle contraction, aldosterone secretion, adrenergic stimulation and renal 
sodium reabsorption are mediated by the AT1 receptor. Ang II also binds to AT2 receptors, 
inducing a counter regulatory vasodilation that is largely mediated by bradykinin and nitric 
oxide (NO, see section 6.3) (Figures 7 and 8). 
 
 
Figure 7. Schematic diagram of the renin angiotensin aldosterone system which shows the 
role of ACE and ACE2 in the metabolism of the various angiotensin peptides (Hamming et al, 
2007). 
33 
The main role of Ang II is the control of Na+ reabsorption through different mechanisms. A 
stronger constriction of the efferent arteriole compared to the afferent arteriole leads to 
enhanced Na+ reabsorption, the blood flow through the vasa recta is reduced preventing 
NaCl and urea to be washed-out of the medulla, the sensitivity of the tubuloglomerular 
feedback increases and the Na+/H+ exchanger actitivity is enhanced. Ang II also stimulates 
the release of aldosterone by the glomerulosa cells in the adrenal cortex, which stimulates 
Na+ reabsorption in collecting tubules. Ang II additionally stimulates thirst and AVP secretion 
in the central nervous system (Boron & Boulpaep, 2005) (Figure 8). 
 
 
 
Figure 8. The renin angiotensin aldosterone system (Boron & Boulpaep, 2005). 
 
The complexity of the classical RAAS regulation of blood pressure was increased with the 
identification of new enzymes regulating the system’s peptides, such as the angiotensin-
converting enzyme 2 (ACE2) and the presence of local RAS. 
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6.2.1 ACE2 / ACEH 
 
ACE2 (ACEH), a homolog of ACE is an essential carboxypeptidase of the RAS that primarily 
cleaves Ang II to Ang (1-7), but also Ang I to Ang (1-9). ACE2 action reduces Ang II 
concentration and counterbalances the action of ACE. Additionally, it has been shown that 
Ang (1–7) mediates vasodilatation, antiproliferation, and apoptosis, thereby opposing the 
effects of Ang II (Figure 7). 
ACE2 was originally identified in two independent studies, a screen for new metalloproteases 
(Tipnis et al, 2000) and a human heart failure ventricle library (Donoghue et al, 2000). It is 
located in the Xp22 locus, contains 18 exons encoding an 805 amino acids type I 
glycoprotein with a 17 amino acids signal peptide and a single transmembrane segment 
(Figure 9). The single HEMGH zinc-binding catalytic domain is encoded by exon 9. 
ACE2 localises to the apical membrane in polarized cells and is downregulated after 
extracellular shedding by the ADAMs family of zinc metalloproteinases (Lambert et al, 2005), 
and by binding of the SARS coronavirus (Imai et al, 2005; Kuba et al, 2005). 
ACE2 recognises the consensus sequence Pro-(1-3 residues)-Pro-hydrophobic amino acid  
cleaving the terminal residue of a variety of peptides such as neurotensin-(1–11), dynorphin 
A-(1–13) (endogenous opioid), β-casomorphin-(1–7), ghrelin and apelin (13 and 36) but not 
bradykinin (Vickers et al, 2002). 
ACE2 was originally described as being expressed in kidney, heart and testis, but further 
investigation identified it in a variety of tissues such as VSMCs, lung, liver, small intestine, 
placenta and brain (Hamming et al, 2007). 
 
Three ace2 null mice models were generated by deleting the catalytic domain encoding exon 
9. As expected from the role of ACE2 in the RAS, the three models led to Ang II increase in 
kidney, heart and plasma as measured by all three groups. The role of ACE2 on heart 
function and blood pressure regulation was investigated due to the expression of ACE2 in 
endothelial cells, smooth muscle cells from intra-myocardial vessels, and cardiac myocytes, 
but the findings were not consistent and remain inconclusive (Crackower et al, 2002; Gurley 
et al, 2006; Yamamoto et al, 2006). The first ace2 knock-out mouse model generated by the 
group of Joseph Penninger confirmed the importance of this protein in heart function and 
morphology. These ace2 null mice had a slight wall thinning of the left ventricle and 
increased heart chamber dimension. This led to a reduction in cardiac contractility and was 
primarily observed in 6 months old male mice. The authors hypothesise that increased Ang II 
levels are responsible for the heart phenotype as it is rescued by additionally knocking the 
ace gene out. This cardiac defect was not observed in the ace2 null mice independently 
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generated by the group of Thomas Coffman, or by the group of Toshio Ogihara. A cardiac 
phenotype was however still evidenced as ace2 null mice had lower heart rates in 3 and 6 
months old mice (Gurley et al, 2006) and an accelerated pressure overload-induced cardiac 
dysfunction from increased local Ang II levels (Yamamoto et al, 2006). 
Since the RAAS controls blood pressure and ACE2 localises to the vascular endothelial cells 
and smooth muscle cells, disruption of the ACE2 component was hypothesised to lead to 
hypertension (Hamming tissue distribution ACE2 2004). Though ACE2 mRNA is 
downregulated in hypertensive rats  (Crackower et al, 2002), comparison of baseline blood 
pressures in the different ace2 knock-out mice models was, similarly to the heart phenotype, 
inconsistent between the different models. A first model only showed hypotension due to the 
decreased cardiac contractility in 6 months old ace2 null mice (Crackower et al, 2002). In the 
second model, there was a slight hypertension in ace2-/y in a C57/Bl6 background of about 7 
mmHg. Chronic Ang II administration increased blood pressure in these mice twice as much 
as in the wild-type controls. Interestingly, the blood pressure of ace2 null mice back-crossed 
in a 129/Sv exhibited no difference when compared to ace2 wild-type littermates whether 
chronically treated with Ang II or not, showing the importance of the background strain when 
measuring blood pressure (Gurley et al, 2006). 
  
The kidney is another important organ implicated in the regulation of blood pressure and 
where ACE2 is highly expressed. In the kidney, ACE2 is expressed on the apical side of the 
proximal tubule with an axial gradient towards the earlier segments (Singer et al, submitted), 
in smooth muscle cells of renal vessels (Hamming et al, 2007), and in glomerular visceral 
and parietal epithelial cells. Angiotensinogen is directly secreted into the tubule lumen, where 
it serves as a substrate for renin or renin-like enzymes increasing local renal interstitial fluid 
Ang II levels to a 1000 times more than in plasma. A disrupted balance between intrarenal 
ACE and ACE2 with consequent high levels of Ang II contributes to progressive renal 
damage. Accordingly, ace2 null mice develop a late onset of glomerulosclerosis (Oudit et al, 
2006) and renal ACE2 expression is decreased in experimental hypertension and diabetes 
(Crackower et al, 2002; Tikellis et al, 2003). 
 
Additionally, ACE2 and possibly Ang II levels in general have surprising effects on amino 
acid and glucose homeostasis. As previously mentioned, ACE2 and its smaller homologue 
Tmem27 control amino acids transporters expression in the small intestine and in the kidney, 
respectively (see sections 5.3.1-5.3.3 and 6.2.2). The work presented in this thesis shows 
the physiological impact of the lack of certain intestinal amino acid transporters in ace2 null 
mice (see section 9). Though no mechanism has been suggested, glucose homeostasis also 
seems to be impaired in ace2 null mice that display selective decrease in first-phase insulin 
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secretion in response to glucose and a progressive impairment of glucose tolerance (Niu et 
al, 2008). 
Finally, the general intestinal RAS system has also been shown to regulate sodium-
dependant glucose transporter 1 (SGLT1) expression in rat small intestine. There, SGLT1-
mediated glucose transport in intestinal ring segments was decreased by exposure to Ang II 
through transporter downregulation, which was reversible by AT1 receptor antagonist 
treatment (Wong et al, 2007). 
Furthermore, ACE2 is not only involved in cardiovascular and renal (patho)physiology, but 
also in diabetes, acute lung disease and pregnancy (Hamming et al, 2007). 
 
 
 
Figure 9. The domain structure of somatic and testis ACE, ACE2, and Tmem27 (Collectrin). 
Each protein is a type I integral membrane protein with a cleaved signal peptide (black), an 
N-terminal ectodomain, a transmembrane domain (blue in ACE; red in ACE2 and Collectrin), 
and a C-terminal cytoplasmic domain. HEMGH: zinc binding active site (Hamming et al, 
2007). 
 
 
37 
6.2.2 Tmem27 / Collectrin 
 
 
Tmem27, or Collectrin, is a homolog of ACE2, sharing 47.8% identity with its non-catalytic 
extracellular, transmembrane and cytosolic domains, but does not contain the catalytic 
activity domain (Figure 9). ACE2 and Tmem27 constitute an ancient gene duplication that 
are always located in close proximity on the same chromosome throughout evolution (Chou, 
gene, 2006). 
Tmem27 was originally described as dramatically upregulated in 5/6 nephrectomized mouse 
kidney (NX-17) in a screen to identify genes involved in glomerular hyperfiltration and 
hypertrophy (Zhang et al, 1999). 
The tmem27 gene localises next to ACE2 on chromomsome Xp22 and encodes a 222 amino 
acid protein with a signal peptide that represents a 32 kDa membrane glycoprotein with a 
single transmembrane segment (Zhang et al, 2001). It was originally described to specifically 
localise to the kidney collecting duct membrane and cytosol, hence the name Collectrin. 
Further studies showed a broader expression in liver, lung, endocrine pancreas and kidney 
proximal tubule brush border membrane where it is necessary for SLC6 amino acid 
transporters expression (Akpinar et al, 2005; Danilczyk et al, 2006; Malakauskas et al, 2007; 
Stoffel et al, 2004). As mentioned earlier, tmem27 null mice exhibit a dramatic decrease of 
SLC6 amino acid transporters in kidney proximal tubule that leads to massive aminoaciduria 
(Danilczyk et al, 2006; Malakauskas et al, 2007). 
The promoter of tmem27 is under the control of both hepatocyte nuclear factor 1 α and β 
(HNF1α and HNF1β). Indeed, a decrease of Tmem27 expression in the hnf1α null mouse 
model is probably responsible for the aminoaciduria component of the general defect of 
proximal tubule reabsorption in these mice (Fanconi syndrome) (Pontoglio et al, 1996). The 
implication of Tmem27 with the maturity onset diabetes of the young (MODY) was then 
investigated, as  mutations in transcription factors HNF1α and HNF1β are responsible for this 
disease along with mutations in the gene encoding glucokinase (MODY2). There were 
however discrepancies in the first reports investigating Tmem27 function in pancreas β-cells 
that have not been solved. Overexpression of Tmem27 in mice showed that it either 
increases glucose-stimulated insulin exocytosis by binding snapin and therefore facilitating 
SNARE complex formation (Fukui et al, 2005), or by increasing β-cell mass (Akpinar et al, 
2005). 
 
Rarer mutations in HNF1β cause polycystic kidney disease additionally to the diabetes 
mellitus. This effect might be linked to the HNF1β-controlled expression of Tmem27 in the 
renal collecting duct where it is heavily expressed in the primary cilium. More specifically, it 
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localizes in the vesicles near the peri-basal body region and bound to β-actin-myosin II-A, 
SNARE and polycystin-2-polaris complexes (Zhang et al, 2007). 
 
 
6.3 Nitric Oxide 
 
Nitric oxide (NO), or endothelium-derived relaxing factor (EDRF) before it was molecularly 
identified, controls basal blood flow and blood pressure. It is also implicated in platlet 
aggregation, disaggregation and adhesion and in immune response by macrophages and 
neutrophils. Professors Robert Furchgott, Louis Ignarro and Ferid Murad received the Nobel 
price in Physiology or Medicine in 1998 for their discoveries concerning "nitric oxide as a 
signalling molecule in the cardiovascular system" (Raju, 2000). 
 
NO is synthesised by NO synthases (NOS) by cleaving the guanidine nitrogen from the 
arginine precursor thereby co-releasing citrulline. Different isoforms of NOS are expressed in 
endothelial cells (eNOS / NOS III), in macrophages and neutrophils (inducible iNOS / NOS II) 
and in neurons (nNOS / NOS I). 
In endothelial cells, eNOS activity is induced by acetylcholine, bradykinin, substance P, 
adenosine nucleotides, Ca2+ as well as shear stress. Intracellular Ca2+ release by these 
factors binds to cytosolic calmodulin (CaM) that then stimulates eNOS. NO being a small 
lipophilic gas with a short half life (in the range of seconds), it freely diffuses through the 
membrane to the neighbouring VSMCs. Activation of guanylyl cyclase by NO in VSMCs 
converts GTP to cGMP, which in turn allows cGMP-dependant kinase to phosphorylate 
various substrates. The myosin light chain kinase (MLCK) is activated and decreases 
interaction between actin and myosin, whereas inactivation of the Sarco/Endoplasmic 
reticulum Ca2+-ATPase (SERCA) decreases cytoplasmic Ca2+ concentration altogether 
leading to VSMC relaxation (Figure 10) (Boron & Boulpaep, 2005). 
Study of NO signalling with NOS competitive inhibitors like L-NMMA or L-NAME (NG-
monomethyl-L-arginine or NG-nitro-L-arginine methyl ester, respectively) showed that there is 
a basal release of NO that regulates blood flow and blood pressure with a greater impact on 
the arterial than on the venous side of circulation (Vallance et al, 1989), as well as a greater 
impact on large arterioles (Griffith & Edwards, 1990).  Importance of NO in systemic blood 
pressure control was later confirmed in the eNOS knock-out mouse model that had 
increased 24 h average blood pressure levels (+15 %), daily range (+44 %), and coefficient 
of variation (+26 %) (Van Vliet et al, 2003). 
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It has been shown that infusion of amino acids increases renal perfusion flow and glomerular 
filtration rate (Castellino et al, 1986). These effects may be mediated by NO, as they were 
inhibited by L-NMMA (Tolins & Raij, 1991). This was however not consistent with studies 
comparing the effect of glycine infusion to that of an amino acid infusion mix. While glycine 
alone also induced hyperfiltration and hyperemia that were attenuated and abolished, 
respectively, by L-NMMA pre-treatment, this was only modestly blunted and ineffective, 
respectively, for the amino acid mix (King et al, 1991). 
 
 
 
Figure 10. Nitric oxide (NO) synthesis cascade leading to smooth muscle cell relaxation. 
sGC: soluble guanylate cyclise (Nussey & Whitehead, 2001). 
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7. Original Research Article: Tissue-specific amino acid 
transporter partners ACE2 and Collectrin differentially 
interact with Hartnup mutations 
 
 
This section contains an original research article that was accepted for publication in 
Gastroenterology and published online on October 30th 2008. 
 
My contribution to this paper concerns the work performed in vivo in ace2 and coll null mice 
which shows that B0AT1 associates with tissue specific Tmem27 (Collectrin) and ACE2 in the 
kidney and in the small intestine, respectively. 
The differential interaction of the associated proteins with wild type and mutations present in 
Hartnup disorder B0AT1 was investigated in X. laevis oocytes by Dr. Simone M. R. Camargo 
with whom first authorship is shared. 
 
The physiological impact of ACE2 loss on growth, metabolic parameters and amino acid 
levels was further investigated and reported in section 7.3. 
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Abbreviation List 
 
AB, antibody 
ACE2, angiotensin-converting enzyme 2 
ace2 -/-, ace2 female null mouse  
ace2 -/y, ace2 male null mouse 
ace2 +/+, ace2 female wild type mouse 
ace2 +/y, ace2 male wild type mouse 
AP substrate, alkaline phosphatase substrate  
B0AT1, Broad range neutral amino acid transporter 1  
BBMV, brush border membrane vesicles 
coll -/y, collectrin male null mouse 
coll +/y, collectrin male wild type mouse 
C-term, Carboxyl-terminal 
HRP substrate, horseradish peroxidase substrate 
KO, knock-out mouse 
MES, 2-(N-morpholino)-ethanesulfonic acid 
MTSEA-biotin, 2-(aminoethyl)-methanethiosulfonate-biotin 
NMDG, N-methyl-D-glucamine 
N-term, Amino-Terminal 
PCR, polymerase chain reaction 
PVDF, Polyvinylidenfluorid 
SARS, Severe acute respiratory syndrome 
SARS-CoV,  SARS coronavirus 
SDS, sodium dodecyl sulfate 
SLC6A19, solute carrier family 6, member 19 
SNP, Single nucleotide polymorphism  
TEVC, two electrode voltage clamp 
Vh, holding voltage 
WT, Wild type 
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Abstract 
Background and aims: Hartnup amino acid transporter B0AT1 (SLC6A19) is the major 
luminal sodium-dependent neutral amino acid transporter of small intestine and kidney 
proximal tubule. The expression of B0AT1 in kidney was recently shown to depend on its 
association with Collectrin (Tmem27), a protein homologous to the membrane anchoring 
domain of angiotensin converting enzyme 2 (ACE2). Since Collectrin is almost absent from 
small intestine, we tested the hypothesis that it is ACE2 that interacts with B0AT1 in 
enterocytes. Furthermore, since B0AT1 expression depends on an associated protein, we 
tested the hypothesis that Hartnup-causing B0AT1 mutations differentially impact on B0AT1 
interaction with intestinal and kidney accessory proteins. Results: Immunofluorescence, co-
immunoprecipitation, and functional experiments using wild type and ace2 null mice 
demonstrate that expression of B0AT1 in small intestine critically depends on ACE2. Co-
expressing new and previously identified Hartnup disorder-causing missense mutations of 
B0AT1 with either Collectrin or ACE2 in Xenopus laevis oocytes shows that the high 
frequency D173N and the newly identified P265L mutant B0AT1 transporters can still be 
activated by ACE2 but not Collectrin coexpression. In contrast, the human A69T and R240Q 
B0AT1 mutants cannot be activated by either of the associated proteins although they function 
as wild type B0AT1 when expressed alone. Conclusion: We thus demonstrate that ACE2 is 
necessary for the expression of the Hartnup transporter in intestine and suggest that the 
differential functional association of mutant B0AT1 transporters with ACE2 and Collectrin in 
intestine and kidney, respectively, participates to the phenotypic heterogeneity of human 
Hartnup disorder. 
  
 
Key words: Epithelial transport, enterocyte, amino acid transport, renin-angiotensin system, 
hereditary aminoaciduria, intestinal absorption 
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Introduction 
Hartnup is an autosomal recessive disorder caused by mutations in the SLC6A19 gene that 
encodes the main epithelial neutral amino acid transporter B0AT11, 2. This disorder is 
characterized by neutral aminoaciduria due to impaired amino acid transport in kidney 
proximal tubule epithelial cells whereas the extent of intestinal transport impairment appears 
to be less consistent. Various other clinical symptoms such as pellagra-like rash, cerebellar 
ataxia or other neurological dysfunctions may be present in affected individuals, while other 
subjects remain, besides aminoaciduria, asymptomatic. Phenotypic variability might be 
partially explained by the differential impact of various mutations and the frequent compound 
heterozygosity.  
Differential phenotypic effects of mutations could arise from differential interactions of 
B0AT1 with tissue-specific modulatory and/or associated proteins. We and others have 
previously shown that B0AT1 requires association with Collectrin for luminal surface 
expression in kidney proximal tubule, whereas Collectrin is nearly absent in small intestine, 
the other major site of B0AT1 expression 3, 4. Intriguingly, the closest homolog of Collectrin is 
the angiotensin-converting enzyme 2 (ACE2), which functions as a key carboxypeptidase 
enzyme in the renin angiotensin system. ACE2 is involved in heart and kidney pathologies 5 
and has been identified as the SARS receptor in vitro 6 and in vivo 7. Importantly, previous 
studies have reported ACE2 expression and SARS-CoV replication in human small intestine 8, 
9.  
We first investigated whether ACE2 associates with B0AT1 in mouse small intestine. 
Immunofluorescence, co-immunoprecipitation and functional data presented here clearly 
demonstrate that ACE2 is the specific partner of B0AT1 in small intestine and thus that the 
accessory protein of B0AT1 is tissue specific.  
We then tested the influence of Collectrin and ACE2 on the function of human B0AT1 
Hartnup-causing mutations in the Xenopus laevis oocyte expression system. Our results 
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suggest that specific defects in interaction with tissue specific accessory proteins may lead to 
differential defects in intestinal versus kidney (re)absorption of neutral amino acids and 
thereby participate to the variability of phenotypes observed in Hartnup subjects. 
 
Methods 
Animals 
The ace2 and collectrin wild-type (WT) and knock-out (KO) mice were housed in standard 
conditions and fed a standard diet. Generation of the KO mice was described elsewhere 3, 5. 
Animals were either anaesthetised and perfused with a fixative solution for localization 
studies or euthanized to remove small intestine and kidneys. Scraped small intestine mucosa 
cells and total kidneys were frozen in liquid nitrogen for subsequent RNA extraction or brush 
border membrane vesicles (BBMV) preparation. All procedures for mice handling were 
according to the Swiss Animal Welfare laws and approved by the Kantonales Veterinäramt 
Zürich. 
Organ fixation 
Male mice were anesthetized with ketamine and xylazine (90 mg/kg body weight, Narketan 
10, Vétoquinol, Lure, France) and Xylazine (10 mg/kg body weight, Xylazin, Streuli, Uznach, 
Switzerland) intraperitoneally and perfused through the left cardiac ventricle with phosphate-
buffered saline (PBS, phosphate buffer, pH 7.4) followed by a buffered paraformaldehyde 
solution (4%, pH 7), as previously described 10. Small intestine was then harvested, incubated 
overnight in paraformaldehyde solution, washed several times with PBS and stored in PBS-
0.02% sodium azide at 4°C. Tissues were then mounted with Kryostat OCT (Medite, 
Nunningen, Switzerland), frozen in liquid propane and stored at – 80°C. 
Immunofluorescence  
Immunofluorescence was performed as previously described 11. Primary antibodies were 
diluted (1:200) for rabbit affinity purified anti-mouse B0AT1 11, and (1:100) for affinity 
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purified goat anti-mouse ACE2 (R&D Systems, Minneapolis, USA). Secondary antibodies 
were diluted (1:500) for Alexa Fluor 488 donkey anti-goat IgG and Alexa Fluor 594 donkey 
anti-rabbit IgG (Molecular Probes, Invitrogen, Carlsbad, USA). Digital images were viewed 
by using a Nikon Eclipse TE300 epifluorescence microscope (Nikon Instruments Inc., 
Melville, USA) equipped with a DS-5M Standard CCD camera (Nikon) and acquired with 
NIS-Elements (Nikon). 
Brush Border Membrane preparations  
Brush Border Membrane Vesicles (BBMV) were prepared from small intestine mucosa cells 
and kidneys using the Mg2+ precipitation technique as described elsewhere 12. 
Western blotting  
Western Blotting was performed as previously described 11. Primary antibodies were diluted 
to: 1:1000 goat affinity purified anti-mouse ACE2 (R&D), 1:1000 goat affinity purified anti-
human ACE2 (R&D), 1:2000 or 1:1000 for rabbit affinity purified anti-mouse or anti-human 
B0AT1, respectively 11 (Pineda, Berlin, Germany) and 1:10000 for mouse anti-mouse β-actin 
(Sigma, St Louis, USA). Secondary antibodies were diluted (1:5000) for ECLTM anti-rabbit or 
anti-goat IgG Horseradish Peroxidase linked fragment from donkey or mouse, respectively 
(Amersham Biosciences, Piscataway, USA and  Pierce, Rockford, USA.) or anti-mouse IgG 
Alkaline Phosphatase Conjugate from mouse (Promega, Madison, USA). Antibody binding 
was detected with Immobilon Western Chemiluminescent HRP or AP substrate (Millipore, 
Billerica, USA) and chemiluminescence visualized with a DIANA III camera (Raytest, 
Dietikon, Switzerland). 
Intestinal Ring Uptake 
Uptake of radiolabelled L-isoleucine was performed as previously described 13 on ileum 
segments, with slight modifications. Briefly, everted ileum segments were incubated in 
bubbling (Oxycarbon) Krebs-Tris Buffer (pH 7.4) containing 1mM L-isoleucine (1 μCi 14C-
L-Ile/ml) for 5 min at 37°C. Ileum segments were dried at 55°C O/N on cellulose (Sartorius 
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AG, Goettingen, Germany) and weighed.  Segments were then lysed in 0.75 N NaOH for 6 h, 
neutralised with 10N HCl and the radioactivity was determined by liquid scintillation. Na+ 
was replaced by N-methyl-D-glucamine (NMDG) in the condition without Na+. Amino acid 
transport was expressed relative to dry tissue weight. 
Identification of new Hartnup mutations 
After informed consent  genomic DNA was obtained from whole blood of Hartnup patients as 
previously published 1. Intronic primers to sequence exons and splice sites of each exon were 
chosen. Primer sequences are available on request. PCR products of each exon were separated 
by electrophoresis on agarose gels and specific bands removed for DNA isolation. This DNA 
was sequenced in both directions using a Beckman Coulter CEQ8000 (Beckman Coulter, 
Fullerton, USA) following the manufacturer's protocol. The absence of each recognized 
missense mutation was confirmed in 100 ethnically matched control alleles. 
Isolation and subcloning of cDNAs and site-directed mutagenesis 
Human (h) B0AT1, ACE2 and Collectrin cDNAs were amplified from human kidney 
Marathon-Ready cDNA (Clontech, Mountain View, CA, USA) by PCR using a proofreading 
polymerase (Pfu, Promega, Madison, USA). The primers used are available upon request. The 
amplified ACE2 and Collectrin cDNAs were subcloned in pcDNA3; mouse (m) ACE2 and 
Collectrin in pcDNA 3.1 hygromycin (Invitrogen, Carlsbad, USA). The B0AT1 was sub-
cloned into a pBlueScript modified Xenopus laevis expression vector containing both the 5’ 
and 3’ ends of the β-globin gene (KSM) kindly provided by Dr. Leila Virkki. For expression 
in Xenopus laevis oocytes the plasmids were linearized and used as template for RNA 
synthesis (mMESSAGEmMACHINE™, Ambion, Austin, USA). The mutation in human 
B0AT1 and ACE2 was performed using quick changes site-directed mutagenesis according to 
the manufacturer (Stratagene, La Jolla, USA). The mutation ACE2-R273Q was shown 
previously to be catalytically inactive but normally expressed 14. The B0AT1 mutations were 
done on the SNP V252I, which has been shown to behave like the wild type. 
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Homology model 
The homology model of human B0AT1 transport was based on the crystal structure of 
LeuTAa (NP_214423) as a template using the I-TASSER server 15. The pdb file was 
visualized using Pymol (DeLano Scientific LLC, Palo Alto, USA).   
Transport studies in Xenopus laevis oocytes.  
Expression studies and influx assays using radiolabeled amino acid tracer were performed in 
X. laevis oocytes after 5 to 9 days expression, as described previously 16. Data is expressed in 
pmol / h / oocyte and values obtained for non-injected oocytes are subtracted. 
Electrophysiology using two-microelectrode voltage clamp 
The two-microelectrode voltage clamp (TEVC) technique was used for the recording of 
whole-cell currents from X. laevis oocytes. Recordings were performed at room temperature 
5-9 days after injection with cRNA. Recordings were carried out as previously described 16 at 
a membrane holding potential (Vh) of −50 mV. To control for batch variation in transporter 
expression and measured current, the data from the selectivity experiment were normalized to 
IL-Ile 10mM. Pooled data are shown as mean ± SEM where n represents the number of pooled 
cells. Experimental protocols were repeated at least twice. Nonlinear regression calculations 
were performed using GraphPad Prism™ Version 4.0 (GraphPad Inc., San Diego, USA).  
Labelling of surface proteins in Xenopus oocytes 
Surface labelling of oocytes expressing human B0AT1 alone or co-expressed with mouse 
ACE2 or human Collectrin  was performed using MTSEA-Biotin (Sigma-Aldrich, 
Switzerland) as previously described 17. Samples were separated on a 10% SDS gel and 
immunoblotted with affinity purified rabbit anti- human B0AT1 antibody (Pineda). Signal 
intensity was quantified with the AIDA Image Analyzer (Raytest).  
Immunoprecipitations 
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Mouse brush border membrane proteins: BBMVs were incubated with serum anti-B0AT1 
polyclonal antibody 11 in EBC solution (20 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.5% NP40) 
at 4°C on a rotator. The immunocomplexes were coupled to Immobilized Protein A/G beads 
(Pierce) O/N at 4°C on a rotator. The beads were washed with NET-N solution (20 mM Tris-
HCl pH 8.0, 100 mM NaCl, 0.5% NP40, 1 mM EDTA), and the immunoprecipitate loaded on 
a polyacrylamide gel. Western Blot was performed as described above with anti-mouse 
B0AT1 antibody to check for B0AT1 immunoprecipitation or anti-mouse ACE2 antibody to 
test ACE2 co-immunoprecipitation. To avoid background staining, Protein A/G coupled to 
Alkaline Phosphatase (AP) was used as a secondary antibody (Pierce). 
Xenopus laevis oocytes: Immunopreciptation of human B0AT1, B0AT1 mutants and human 
ACE2 was performed as previously described 18. Briefly oocytes were lysed in EBC buffer (as 
described for BBMV) and the supernatant was first incubated with serum anti-human B0AT1 
and subsequently with Immobilized Protein A/G beads (Pierce) O/N at 4°C on a rotator. 
Western Blot was performed as described above to test for human ACE2 co-
immunoprecipitation. 
Statistics 
Data are presented as means ± standard error of the mean (SEM). Analyses were done by 
running the GraphPad Prism 4.0 software (GraphPad).  Between-group comparisons were 
performed by Student's unpaired t test. Multiple comparisons within groups were performed 
by repeated-measures oneway ANOVA, followed by Tukey post test. Statistical significance 
was accepted at P < 0.05. 
 
Results 
 
ACE2 is the intestinal partner of the amino acid transporter B0AT1 
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We first assessed the potential in vivo role of ACE2 as intestinal B0AT1 associated protein by 
investigating the B0AT1 expression in ace2 null mice 5. Remarkably, B0AT1 protein was 
completely absent in small intestine brush border membranes of mice lacking ACE2 (Figure 
1A, B) whereas it was normally expressed in kidney (Figure 1B). This organ distribution of 
B0AT1 in ace2 null mice mirrors the situation observed in collectrin null mice, where B0AT1 
is absent in kidney and, as shown in this study, normally expressed in small intestine (Figure 
1B). Furthermore, ACE2 was co-immunoprecipitated with B0AT1 from intestinal brush 
border membranes of wild type mice, demonstrating in vivo interaction (Figure 1C).  
The function of B0AT1 was also shown to depend on ACE2 in mouse intestine. We observed 
that the lack of B0AT1 protein expression in the intestine of ace2-/y mice abolished the Na+-
dependant portion of L-isoleucine transport measured in intestinal rings (Figure 1D). The total 
(in the presence of Na+) but not the sodium-independent transport was dramatically reduced 
when compared to the wild type littermates. The equivalent effect was previously shown in 
kidney brush border membrane vesicles of collectrin -/- mice, where the transport was also 
reduced 3.  These data show that ACE2 is essential for expression and function of B0AT1 in 
intestine whereas Collectrin controls B0AT1 expression in the kidney. 
 
ACE2 and Collectrin increase the function of human Hartnup transporter B0AT1 in 
vitro 
The tissue-specific associated proteins Collectrin and ACE2 expressed in Xenopus laevis 
oocytes mimicked their effect in vivo on B0AT1 by stimulating its transport function. 
Expressed alone in oocytes human B0AT1 induced a low amino acid transport rate as shown 
by us and others previously 1, 2. We show here that its co-expression with mouse or human 
ACE2, or human Collectrin increases the transport function ~10-fold (Supplementary Figure 
1A; see supplementary material online at www.gastrojournal.org ). The mouse ortholog of 
Collectrin did not activate human B0AT1, although it has been shown to be effective on 
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mouse B0AT1 3. We have as yet no explanation for this differential impact of the collectrin 
orthologs in the X. laevis expression system. Different from Collectrin, ACE2 has one 
catalytic site. It is a carboxypeptidase, and converts Angiotensin (Ang) I and II to Ang (1-9) 
and (1-7), respectively 19, 20, functionally antagonizing its homolog ACE. We analyze the role 
of the catalytic activity of ACE2 in the functional interaction with B0AT1 (Supplementary 
Figure 1B; see supplementary material online at www.gastrojournal.org). The catalytically 
dead mutant (ACE2 R273Q)14 was as efficient as the wild type in enhancing the B0AT1 
function suggesting that it is not necessary for the interaction. This was expected since human 
Collectrin shares 48% identity with ACE2 at the level of its carboxyl-terminal membrane 
anchor region but entirely lacks the extracellular peptidase domain 21. 
The amino acid selectivity, ion dependence and kinetic characteristics of human B0AT1 co-
expressed with ACE2 are, besides a much higher maximal transport rate, very similar to those 
previously published for human B0AT1 expressed alone 1 (Supplementary Figure 2 A-E; see 
supplementary material online at www.gastrojournal.org). 
 
Differential interaction of accessory proteins with B0AT1 Hartnup mutations  
To address the question whether Hartnup mutations impact on the interaction of B0AT1 with 
its accessory proteins ACE2 and/or Collectrin, we expressed missense mutations alone or 
together with either accessory protein in X. laevis oocytes and analysed their transport 
function and surface expression. Beside five previously described missense mutations and one 
non-synonymous single nucleotide polymorphism (SNP), we characterized four new missense 
mutations identified in patients with neutral aminoaciduria characteristic of Hartnup disorder 
belonging to 4 different families (Table 1), (Supplementary Figure 3A-D; see supplementary 
material online at www.gastrojournal.org) 1, 2. The non-synonymous SNP V252I essentially 
behaved as wild-type B0AT1 when co-expressed with Collectrin and ACE2 (Figure 2A upper 
and middle panels). Interestingly, the observed two to three-fold increase in B0AT1 surface 
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expression measured by surface biotinylation only partially explains the almost ten-fold 
increase in surface transport function induced by co-expression with Collectrin or ACE2 
(Figure 2A lower panel and representative Western blot).   
Surprisingly, Collectrin and ACE2 co-expression differentially impacted on the surface 
expression and function of the two B0AT1 mutants D173N and P265L (Figure 2B). In both 
cases, co-expression with ACE2 increased the transport rate whereas co-expression with 
Collectrin either had the opposite effect or no effect (Figure 2B upper panel). The transport 
function of these mutants was shown to be Na+-dependent as for wild-type B0AT1 (Figure 3 
upper and middle panels). Surface biotinylation experiments suggested that the differential 
function of these B0AT1 mutants with the two associated proteins is due, in the case of 
D173N, to a difference in surface expression, whereas the surface expression appeared in the 
case of P265L to be similar with both associated protein (Figure 2B lower panel and 
representative Western blot). Finally, the mutants D173N and P265L co-precipitated with 
human ACE2, confirming that they interact with ACE2 (Figure 2D).  
We next analyzed the two B0AT1 mutations A69T and R240Q that when expressed alone 
display the same L-isoleucine transport function and ion dependence as wild type B0AT1, 
whereas their transport function was not activated in the presence of either associated protein 
(Figure 2C upper and middle panels and Figure 3 lower panel). In the case of the newly 
described A69T, this was particularly surprising, since its surface expression was increased 
two to three-fold by co-expression with both accessory proteins (Figure 2C lower panel and 
representative Western blot) and its interaction with ACE2 confirmed by co-
immunoprecipitation (Figure 2D). In contrast, the surface expression of R240Q did not appear 
to be increased by the presence of the accessory proteins (Figure 2C lower panel and 
representative Western blot), although the mutant transporter was co-immunoprecipitated 
with human ACE2 to some extent (Figure 2D).  
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The mutations R57C, L242P, and E501K have previously been tested by expression in X. 
laevis oocytes, and showed no transport capacity 1, 2. Co-expression of these mutants with 
Collectrin and ACE2 did not change their impaired function and did not affect their cell 
surface expression (Figure 4). Similarly, the newly described mutations G93R and P579L lack 
function also in the presence of associated proteins. However, the surface expression of G93R 
was selectively increased by ACE2 (Figure 4 lower panel and representative Western blot).  
 
Discussion 
Recently we have reported that Collectrin (Tmem27) associates with and controls the 
expression of B0AT1 in kidney proximal tubule 3, 4. In this study, we demonstrated a novel 
and unexpected function of the important renin-angiotensin system enzyme ACE2 that 
associates with the luminal amino acid transporter B0AT1 in small intestine and thereby 
controls its surface expression and function.  B0AT1 associates in a tissue specific manner 
with ACE2 in small intestine and with Collectrin in the kidney. Thus, ace2 and collectrin null 
mice can be used to study the role of the neutral amino acid transporter B0AT1 in kidney and 
intestine independently.  
The same effect was observed on human B0AT1 ortholog expressed in the heterologous 
expression systems, Xenopus laevis oocytes. The co-expression of the two accessory proteins, 
ACE2 or Collectrin, increased the transport rate and the cell surface expression of the 
transporter. The analysis of the function and surface expression of B0AT1-Hartnup causing 
mutations expressed alone or together with the two partner proteins allowed us to discriminate 
classes of mutants that might differentially impact on the phenotype of the patients.  
The Hartnup-causing mutations in B0AT1 are localized throughout the protein, as shown on 
the homology model depicted in Figure 5. This is also the case for the largest class of 
mutations mentioned here, the “dead” mutants, three of which were published earlier (R57C, 
L242P, E501K1, 2) and two of which are newly described here (G93R and P579L) 
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(Supplementary Figure 3 C and D; see supplementary material online at 
www.gastrojournal.org). These mutants do not display any measurable function which is 
consistent with the fact that, with one exception, they do not reach the plasma membrane, 
neither when expressed alone, nor upon co-expression with associated proteins. 
The second class of mutants corresponds to those which expressed alone function as wild type 
B0AT1 but are not stimulated by either associated protein. In the case R240Q, its surface 
expression is not increased upon co-expression with ACE2 or Collectrin, but co-
immunoprecipitation demonstrates that its interaction with ACE2 is not abolished. Assuming 
a qualitative effect of the R240Q mutation on this interaction, our observation is nonetheless 
potentially compatible with the hypothesis recently put forward by the group of Broer, namely 
that the localization of this mutation at the surface of B0AT1 might impact on the interaction 
with accessory proteins 22. Further studies are necessary to clarify the mechanism by which 
this mutation, initially classified as a SNP, prevents the normal activation of B0AT1 by the 
accessory proteins. In contrast, in the case of the other functional mutant of this class A69T, 
an increase in cell surface expression of this mutant B0AT1 was demonstrated upon 
interaction with the associated proteins (Figure 2C and D). One possible explanation of why 
the increase in surface-expression did not lead to an increase in transport rate is that 
ACE2/A69T-B0AT1 heterodimers reaching the cell surface remain inactive, meaning that the 
associated protein inhibits the function of A69T-B0AT1. The fact that the residue mutated in 
A69T is part of a highly conserved motif (NGGGAF) shown to undergo conformational 
changes during the transport cycle is compatible with this hypothesis 23. Additionally, that the 
co-expression of ACE2 or Collectrin apparently activates the transport rate of wild type 
B0AT1 several-fold more than it increases its surface expression (~10-fold versus ~2.5-fold) 
also suggests that associated proteins may impact on transporter function, though normally by 
increasing the cycling rate.  
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The most intriguing class of mutants in regards to its potential phenotypic impact is 
represented by D173N and the newly described P265L. These mutants differentially interact 
with the two tissue-specific accessory proteins such that their function is stimulated only by 
the intestine-specific associated protein ACE2. Interestingly, the D173N allele is relatively 
frequent in unrelated Hartnup pedigrees and can also be observed in healthy Caucasians with 
a high heterozygote frequency (1:122 healthy individuals) 2, 24. We know of no potential 
selective advantage for heterozygous carriers that explains the persistence and geographic 
spread of this mutant allele 25, 26. The selective functional interaction of D173N with the 
intestinal accessory protein ACE2 might prevent deleterious effects due to a lack of amino 
acid absorption and thereby allowing the “survival” of this frequent allele. Although as yet no 
evidence of genotype-phenotype relationship performed in patients were reported, studies 
performed long before the identification of the Hartnup transporter have shown that intestinal 
amino acid absorption differs between Hartnup subjects 27, 28. 
Taken together, our data demonstrate that the expression and function of the main epithelial 
amino acid transporter is modulated by tissue-specific accessory proteins. Moreover, the 
intriguing fact that these accessory proteins can interact differentially with Hartnup mutations 
and thereby differentially affect kidney and intestinal amino acid transport function suggests 
that Collectrin and ACE2 may also contribute significantly to the phenotypic heterogeneity 
among individuals with Hartnup disorder. 
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Table 1: Missense mutations in the SLC6A19/human B0AT1 gene described in subjects 
with Hartnup disorder. 
 
Protein wt mutation Position from the atg Position in the protein 
R57C1 Cgc Tgc 169 1st TMS 
*A69T Gcc Acc 205 2nd TMS 
*G93R Ggg Agg 277 2nd TMS 
D173N2 Gac Aac 517 2nd EL 
R240Q2 cGa cAa 719 3th EL 
L242P2 cTg cCg 725 3th EL 
*P265L cCg cTg 794 6th TMS 
E501K2 Gag Aag 1501 10th TMS 
*P579L Ccg Tcg 1735 6th EL 
New mutations (*) identified in this study. The previously published mutations by 
Kleta et al. 1 and Seow et al. 2 are also listed. R240Q was initially described as SNP 
by Seow et al2. TMS = transmembrane segment, EL = extracellular loop. 
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Figure 1.  ACE2 and B0AT1 co-localization and functional interaction. 
(A) Immunofluorescence analysis shows that B0AT1 protein expression is lost in small 
intestine of ace2 null mice. Small intestine sections from ace2+/y and ace2-/y were co-labelled 
with antibodies against ACE2 (green) and B0AT1 (red), and additionally viewed by phase 
contrast (PC). (B) Western blot analysis shows that B0AT1 is absent in small intestine but 
present in kidney brush border membranes of ace2 null mice, whereas B0AT1 is expressed in 
small intestine and absent from kidney brush border membranes in coll null mice. The loading 
of brush border membranes (2.5-20 μg) was tested using a β-actin antibody (βA). Note that 
male ace2+/y or ace2-/y and female ace2+/+ or ace2-/- mice were used with similar results.  (C) 
Co-immunoprecipitation shows interaction of ACE2 with B0AT1 in mouse small intestine. 
Complexes were immunoprecipitated (IP) from small intestine brush border membrane 
vesicles (BBMVs) using anti-B0AT1 antibody (AB) and analysed by Western Blot (WB) 
using anti-mouse ACE2 antibody. (D) Na+-dependant uptake of L-isoleucine (L-Ile) is 
abolished in ileum segments from ace2-/y mice. The transport was measured in the presence 
(empty bar) and in the absence (solid bar) of sodium. Data points represent means values of 4 
intestinal ring uptakes from independent experiments ± SEM, ***p<0.001, ns = not 
significant.  
Figure 2.  Differential function of Hartnup mutations co-expressed with Collectrin or 
ACE2 in X. laevis oocytes. Wild type and mutant human B0AT1 are shown in this figure as 
three groups with different functional characteristics and labelled A-C.  (A) The transport 
function and the surface expression of both wild type and non synonymous SNP V252I of 
B0AT1 are increased by co-expression with human Collectrin or  mouse ACE2.  (B) The 
relatively low transport activity of B0AT1 D173N and P265L mutants expressed alone is 
increased by co-expression with ACE2 but not with Collectrin. The surface expression of the 
D173N mutant is also significantly increased by co-expression with ACE2.  (C) The wild 
type-like function of the A69T or R240Q mutants expressed alone is not increased in the 
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presence of Collectrin or ACE2 although; in the case of A69T its surface expression is 
increased. The upper panels of A-C show the transport function measured as radiolabelled L-
isoleucine (L-Ile) uptake (means ± SEM of 13-31 oocytes from 3 independent experiments) 
and the middle panel the transport function as current measured by TEVC (9-11 oocytes from 
3 batches). *P<0.05, ***P<0.001. The lower panels show the surface expression assayed by 
Western blot using surface-biotinylated proteins and a representative Western blot. The data 
correspond to the means ± SEM (n = 3-5 independent experiments) of the results normalized 
to the value obtained for B0AT1 expressed alone. For the transport experiments the 
significance was evaluated using ANOVA with Tuckey post-test and for the surface 
biotinylation the comparison of means was done by unpaired t test.  (D) B0AT1 and the 
mutants D173N, P265L, R240Q and A69T interact with ACE2 in X. laevis oocytes. The 
transporters expressed alone or together with human ACE2 were immunoprecipitated (IP) 
from oocyte lysates using anti-human B0AT1 antibody and complexes were analysed by 
Western Blot (WB) using anti-human ACE2 antibody. NI = non-injected.  
 
Figure 3. The ion dependency of D173N, P265L, A69T and R240Q co-expressed with 
ACE2 or Collectrin is not altered: Transport is Na+- but not Cl--dependent. Wild type 
human B0AT1 (WT), and the mutants D173N, P265L, A69T and R240Q were expressed 
alone or with human Collectrin or mouse ACE2. The ion dependence was tested by 
substituting Na+ with NMDG (n-methyl-D-glucamine) and substituting Cl- with gluconate. 
Function was assayed by influx of radiolabeled L-isoleucine (L-Ile). For each mutation, three 
independent experiments (15-24 oocytes) were pooled. Comparison of means was done by 
analysis of the variances (ANOVA) with Tuckey as post test. Data represent means ± SEM. * 
p<0.05, **p<0.01, ***p<0.001. ns, not significant.  
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Figure 4. The B0AT1 mutants R57C, G93R, L242P, E501K and P579L exhibit no 
transport activity when expressed alone or co-expressed with Collectrin or ACE2. 
Function was assayed by influx of radiolabeled L-isoleucine (L-Ile) (upper panels) or TEVC 
(middle panels). For each mutant three independent experiments (13-31 oocytes for influx and 
9-11 for TEVC) were pooled. Comparison of means was done by analysis of the variances 
(ANOVA) with Tuckey as post test. Data represent means ± SEM. ns, not significant. Cell 
surface expression of labelled proteins (lower panels) was analysed by Western blot. The 
bands were quantified and data normalized to the values obtained from oocytes expressing 
B0AT1 proteins alone. For each mutation three to four independent experiments were pooled. 
Comparison of means was done by unpaired t test. Data represent means ± SEM. * p<0.05. 
ns, not significant.  
 
 Figure 5.  Missense mutations in the SLC6A19 gene causing Hartnup disorder. The 
model of B0AT1 is based on the Slc6 bacterial homologue from Aquifex aeolicus LeuTAa 29 
and the transmembrane segments are numbered. The localization of mutations causing a loss 
of surface expression (R57, G93, L242, E501, P579) are depicted in the left panel. The sites 
of mutations leading to a differential interaction with the two accessory proteins (D173 and 
P265) are depicted as black spheres on the middle panel, and the sites of the mutations 
preventing both accessory proteins of stimulating the transport function are depicted on the 
right panel (A69 and R240). 
 
 
Appendix 
Supplementary data 
Supplementary data associated with this article can be found in the online version. 
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Tissue-specific amino acid transporter partners ACE2 and Collectrin 
differentially interact with Hartnup mutations 
 
Simone M. R. Camargo*1, Dustin Singer*1, Victoria Makrides1, Katja Huggel1, Klaas M. Pos, 
Carsten A. Wagner1, Keiji Kuba2, Ursula Danilczyk2, Flemming Skovby4, Robert Kleta3, 
Josef M. Penninger2, and François Verrey1     * These authors contributed equally to this work 
 
Supplementary Figure 1. Function of human B0AT1 co-expressed with orthologs of 
Collectrin and ACE2 in X. laevis oocytes 
(A) Co-expression of ACE2 or human Collectrin increases B0AT1 function in X. laevis 
oocytes. Tracer flux experiments (upper graph, n = 16-32) and two-electrode voltage clamp 
(TEVC, lower graph, n = 11) show that human B0AT1 (hB0AT1) co-expressed with human 
ACE2 (hACE2), mouse ACE2 (mACE2), or human Collectrin (hColl) transports L-isoleucine 
more efficiently than when expressed alone or in combination with mouse Collectrin (mColl). 
Data points represent means ± SEM.  ***p<0.001. ns, no significant. 
(B) Human B0AT1 function is increased by co-expressed human ACE2 independent of its 
protease activity. The protease-dead human ACE2 mutant (ACE2 R273Q) stimulated the 
human B0AT1-mediated L-isoleucine influx to the same extent as wild type human ACE2. 
Data points represent means ± SEM (n=15-16). ns, not significant. 
 
Supplementary Figure 2. Functional characterization of the complex formed by human 
B0AT1 and ACE2 in X. laevis oocytes. (A) The amino acid transport by human B0AT1 co-
expressed with mouse ACE2 in X. laevis oocytes is Na+-, but not Cl--dependent. The ion 
dependence was tested by substituting Na+ by NMDG (n-methyl-D-glucamine) or Li+, and Cl- 
by gluconate in the superfusion solution used for TEVC. The values were normalized to the 
current obtained by superfusion of the oocytes with 10 mM L-isoleucine in solution 
containing Na+ and Cl- (Inorm). Comparison of means was done by analysis of the variances 
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(ANOVA) with Tuckey as post test. Each data point represents the mean ± SEM (n=16). *** 
p< 0.001. 
(B) Amino acid transport by human B0AT1 co-expressed with mouse ACE2 in X. laevis 
oocytes is maximal at neutral pH. The pH dependence of the transport was measured by 
TEVC in oocytes clamped at –50 mV and superfused with Na+-solution buffered at pH 5.5, 
6.5, 7.4 or 8.0. Values were normalized to the current obtained by superfusion of oocytes with 
10 mM L-isoleucine in solution pH 7.4 (Inorm). Comparison of means was done by analysis of 
the variances (ANOVA) with Tuckey as post test. Each data point represents the mean ± SEM 
(n = 9). * p < 0.05, ** p < 0.01.  
(C-E) Human B0AT1 co-expressed with ACE2 transports a broad range of neutral amino 
acids with low affinity. (C), The substrate selectivity of human B0AT1 co-expressed with 
mouse ACE2 was measured by TEVC in oocytes clamped at –50 mV and superfused with 
Na+ solution containing 1 mM (open bars) or 10 mM (solid bars) of amino acids. The currents 
induced by the amino acids were normalized to the currents obtained in oocytes perfused with 
10 mM L-isoleucine (Inorm). Data are shown as mean values ± SEM (n = 8-11) and the amino 
acids are indicated in single letter code. (D, E), The K0.5 and Vmax for L-isoleucine and Na+ of 
human B0AT1 co-expressed with mouse ACE2 was estimated using TEVC. For the Na+ 
concentration dependence experiments the cells were first equilibrated with the indicated Na+ 
concentration (0, 1, 5, 10, 30, 50, 70, and 100 mM) before the perfusate containing L-
isoleucine (10 mM) was applied. For the L-isoleucine concentration dependence experiments, 
the cells were perfused with increasing concentrations of L-isoleucine (0.1, 0.3, 1, 3, and 10 
mM). The continuous line is the nonlinear regression fit of the Michaelis-Menten equation to 
the data. Each data point represents the mean ± SEM (C, n = 26-27, for panel D, n = 10-22).  
 
Supplementary Figure 3. Pedigrees of four families with new Hartnup disorder 
mutations. (A) Danish pedigree: two of three siblings were compound heterozygous for 
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P265L and L242P. The symptoms observed were quite diverse between the two sisters. The 
younger one was diagnosed having Hartnup disorder in early childhood due to pellagra like 
skin rash and an atactic gait which improved upon niacin administration 1. The older affected 
sibling never showed skin pathologies nor ataxia. (B) Another Danish pedigree, where the 
only child affected was a compound heterozygous for A69T and the original Hartnup 
mutation IVS8+2T>G. This patient was the first child of unrelated parents and was diagnosed 
at one year of age after a suspected seizure prompted a metabolic screening of urine. Plasma 
amino acids and electroencephalography were normal. The patient subsequently had normal 
growth and development without epilepsy, ataxia or pellagra. (C) The other Danish patient 
was a compound heterozygous for P579L and the original Hartnup mutation IVS8+2T>G. 
This patient was the second child of unrelated parents and was diagnosed at two years of age 
after onset of partial complex epilepsy with great difficulty to control seizures. The patient 
had normal plasma amino acids and never had ataxia or pellagra. (D) Another patient from a 
German family was diagnosed as homozygous for the new missense mutation G93R. This 
patient was diagnosed at six years of age during a migraine workup and also never had ataxia 
or pellagra. The affected subjects are depicted as filled symbols.  
References 
1. Nielsen EG, Vedso S, Zimmermann-Nielsen C. Hartnup disease in three siblings. Dan 
Med Bull 1966;13:155-61. 
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8. Manuscript: Orphan transporter SLC6A18 is renal neutral 
amino acid transporter B0AT3 
 
This section contains the above mentioned manuscript that has been submitted to the 
Journal of Biological Chemistry on October 3rd 2008. The editor sent it back on November 4th 
for additional experiments. 
 
 
Dr. Simone M. R. Camargo significantly contributed to this research article by showing the 
amino acid selectivity, the Na+ and Cl- dependence and the kinetic parameters of B0AT3 in 
vitro in X. laevis oocytes. 
 
My contribution to the manuscript concerns the remaining work in vivo. Namely, the 
phenotypic characterisation of the slc6a18 mouse model in metabolic cages and the blood 
pressure measurements using the telemetry implantation system, as well as the work with  
the tmem27 and the ace2 null mice to resolve the B0AT3 associated protein issue in vivo.
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The orphan transporter Slc6a18 (XT2) is 
highly expressed at the luminal membrane of 
kidney proximal tubules and displays ~50% 
identity with Slc6a19 (B0AT1) which is the main 
neutral amino acid transporter in both kidney 
and small intestine. As yet, the amino acid 
transport function of XT2 had only been 
experimentally supported by the urinary 
glycine loss observed in xt2 null mice. We 
report here that in Xenopus laevis oocytes, co-
expressed angiotensin-converting enzyme 2 
(ACE2) associates with XT2 and leads to its 
cell-surface expression and reveals its function 
as an electroneutral Na+- and Cl--dependant 
neutral amino acid transporter. In contrast to 
its association with ACE2 observed in Xenopus 
laevis oocytes, our experiments with ace2 and 
collectrin null mice demonstrate that in vivo it is 
Collectrin, a smaller homologue of ACE2, that 
is required for functional expression of XT2 in 
kidney. To assess the function of XT2 in vivo, 
we re-analysed its knock-out mouse model after 
more than 10 generations of backcrossing into 
C57BL/6 background. Next to the previously 
published glycinuria, we observed a urinary 
loss of several other, in particular beta-
branched and small neutral amino acids. Using 
telemetry, we confirmed the previously 
described link of XT2 absence with 
hypertension, but only in physically restrained 
animals. Taken together, our data indicate that 
the formerly orphan transporter XT2 functions 
as a sodium and chloride dependent neutral 
amino acid transporter that we propose to 
rename B0AT3. 
 
The SLC6 family is composed of a variety of 
transporters that transfer small organic solutes such 
as neurotransmitters and amino acids across the 
plasma membrane. These substrates are co-
transported with sodium and in many cases also 
with chloride. The substrates transported by most 
of the different family members have been 
identified and include neurotransmitters 
((nor)epinephrine, dopamine, serotonin, GABA), 
osmolytes (taurine, creatinine) and amino acids. 
Despite this extensive characterisation, no data 
directly demonstrating the function of XT2 
(Slc6a18) in an expression system have been 
reported. In particular, the expression of XT2 in 
Xenopus laevis oocytes and cultured mammalian 
cells failed to result in uptake of a variety of tested 
substrates (1,2). 
However, XT2 exhibits approximately 50% 
identity to B0AT1 (Slc6a19), the Na+ cotransporter 
of neutral amino acids the defect of which causes 
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Hartnup disorder. The XT2 gene is arranged in 
tandem with that of B0AT1 (Slc6a19) on 
chromosome 5 in human and chromosome 13 in 
mouse, and thus presumably arose by gene 
duplication. A cloning study identified, besides the 
A12 isoform that resembles most the other Slc6 
family members, five shorter transcripts the 
physiological significance of which is not 
established (1). In a localization study performed 
using mouse tissues, we have shown that XT2 is 
mainly expressed in the kidney, where it localises 
to the brush border membrane of the late proximal 
tubule (S2, S3), in a complementary fashion to 
B0AT1 that localises to the early proximal tubule 
(S1) (3). 
A xt2 null mouse model was generated and 
analyzed previously (2). The high amounts of 
glycine found in the urine of these mice supported 
the hypothesis that the orphan gene product XT2 
functions as an amino acid transporter. Brush 
border membrane vesicles uptake additionally 
evidenced its function as a high affinity transport 
system of glycine. Surprisingly, the xt2 null mice 
displayed a systolic blood pressure that was 15 - 
20 mmHg higher than that of their wild-type 
littermates, a difference that was abolished upon 
glycine supplementation in drinking water. Such 
an impact of XT2 on blood pressure was however 
not confirmed in human, where a SNP within the 
SLC6A18 gene present in 46.7% of a general 
Japanese population corresponds to a nonsense 
mutation (Y319X) presumably leading to a loss of 
function, and is not associated with hypertension 
(4). 
We have recently demonstrated that in the 
proximal kidney tubule, the expression of Slc6 B0 
cluster amino acid transporters requires their 
association with Collectrin (Tmem27, Coll), a 
membrane protein homologous to the membrane 
anchor domain of the renin angiotensin system 
enzyme ACE2 (5). Furthermore, we have shown 
that the enzyme ACE2, highly expressed in kidney 
and intestine, plays the role of associated protein in 
small intestine for luminal Slc6 amino acid 
transporters (S.M.R. Camargo and D. Singer et al., 
submitted)†. 
The first aim of the present study was 
therefore to retest the function of XT2 in the X. 
laevis expression system using co-expression of 
both the kidney and the small intestine associated 
proteins Coll and ACE2, and second, to retest the 
impact of the absence of XT2 in the xt2 null mouse 
model after backcrossing it more than 10 times 
into C57BL/6 background. It appears, based on 
telemetric measurements, that XT2 is involved in 
blood pressure control only under stress conditions 
in the C57BL/6. We show in this study that the 
product of Slc6a18 called XT2 is a Na+- and Cl--
dependent neutral amino acid transporter that in 
contrast to B0AT1 is not electrogenic and displays 
a higher apparent affinity and a different 
preference for its substrates. Because of its broad 
transport selectivity for neutral amino acids we 
suggest to rename it B0AT3. 
 
Experimental Procedures 
 
cRNA preparation of mouse XT2, Collectrin 
and ACE2 - The constructs of the A12 isoform of 
mouse XT2-KSM, Collectrin-pcDNA3.1Hygro 
and ACE2-pcDNA3 were linearized and used as 
template for RNA synthesis (mMESSAGE 
mMACHINE, Ambion, Austin, Texas, USA). 
Transport studies in X. leavis oocytes- 
Expression studies and uptake measurements in X. 
leavis oocytes were performed as described 
previously (6). Ten minutes uptakes were 
performed with buffer containing 0.1 mM of the 
corresponding L-AA (2 uCi 14C-L-AA / ml or 20 
uCi 3H-L-AA / ml). All experiments were done in 
buffer containing NaCl (100 mM) or NMDG-Cl 
(100 mM) for ion dependency experiments. 
Chloride was substituted by corresponding 
gluconate (Glc) salts. Kinetics experiments were 
performed with increasing concentrations of L-Ile 
(0.01, 0.03, 0.1, 0.3, and 1 mM) or L-Gly (0.01, 
0.1, 0.3, 1, and 3 mM), in the presence of NaCl. 
Data is expressed in pmol / h / oocyte and values 
obtained for non-injected oocytes are subtracted. 
Multiple comparisons within groups were 
performed by repeated-measures one way 
ANOVA, followed by Tukey post test. 
Animals - The ace2 and collectrin wild-type 
and knock-out mice were housed in standard 
conditions and fed a standard diet. Generation of 
the knock-out mice was described elsewhere (5,7). 
All procedures for mice handling were according 
to the Swiss Animal Welfare laws and approved by 
the Kantonales Veterinäramt Zürich. 
Metabolic Cages - Animals were adapted to 
metabolic cages (Tecniplast, Buguggiate, Italy) for 
3 days before data collection, where they had free 
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access to standard mouse diet (18.5% crude 
protein, Kliba-Nafag, Kaiseraugst, Switzerland) 
and drinking water. After a first day of data 
collection in standard conditions, the diet was 
either switched to low protein (<0.5% crude 
protein, Kliba-Nafag) for two days or water access 
was removed for 24 h. Daily food / water intake, 
urine / feces output and body weights were 
measured. Urinary pH was measured using a pH 
microelectrode (691 pH-meter, Metrohm). Urinary 
creatinine was measured by the Jaffe method (8). 
Urinary electrolytes (Na+, K+, Ca2+, Mg2+, Cl-, 
SO42-) were measured by ion chromatography 
(Metrohm ion chromatograph, Herisau, 
Switzerland). 
Amino acid analysis - Mouse blood was 
collected by decapitation and 1 μl of heparin-Na+ 
25000 I.E./5 ml (B. Braun, Melsungen, Germany) 
was added. Plasma was collected after 
centrifugation at 8000 rpm and 4°C. Ice-cold 
methanol deproteinization of the plasma was 
performed as described elsewhere (9). Hundred 
microliters of deproteinised sample was dried and 
resuspended in 45 μl of borate buffer. Samples 
were then derivatized using AccQ Tag (Waters, 
Milford, USA) and analyzed on an Acquity UPLC 
(Waters) according to the manufacturers 
instructions by the Functional Genomics Center 
Zurich (FGCZ) (10). 
One microliter mouse urine collected over 24 h 
was diluted up to 100 μl by 50 mM HCl containing 
the internal standards norvaline and sarcosine in a 
concentration of 50 pmol/μl. The solutions were 
centrifuged, and transferred into new hydrolysing 
tube. One microliter was injected for pre-column 
derivatization with ortho-phthaldialdehyde (OPA) 
and analyzed on an Amino Quant amino acid 
analyzer (Agilent Technologies GmbH, Böblingen, 
Germany) at the Functional Genomics Center 
Zurich (FGCZ). 
RNA and real time qRT-PCR - RNA was 
extracted from frozen kidneys and real time qRT-
PCR was performed as previously described (3). 
Three samples per mouse and genotype were run 
and the abundance of the target mRNAs was 
calculated relative to Hypoxanthine Guanine 
Phosphoribosyltransferase (HPRT) or 
Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as a reference. Relative expression 
ratios were calculated as R = 2(Ct(reference) – Ct(test)). Ct 
: cycle number at the threshold, test : tested 
mRNAs. Primers and probes were chosen as 
described elsewhere for B0AT1 (3), XT3 (3), SIT1 
(3), XT2 (3), ACE2 (11), Coll (5), GAPDH (3) and 
HPRT (12). 
Protein Preparation and Western blot Analysis 
- Oocyte homogenization and protein preparation 
was done as described previously (13). For 
immunoprecipitation, the lysate equivalent to 8 
oocytes was coupled to 25 μl of anti-XT2 serum 
(3) in EBC solution (20 mM Tris-HCl pH 8.0, 120 
mM NaCl, 0.5% NP40) for 8 h at 4°C on a rotator. 
The immunocomplexes were coupled to 
Immobilized Protein A/G beads (Pierce, Rockford, 
USA) O/N at 4°C on a rotator. The beads were 
washed 6 times with NET-N solution (20 mM 
Tris-HCl pH 8.0, 100 mM NaCl, 0.5% NP40, 1 
mM EDTA), and the immunoprecipitate was 
eluted, denatured and reduced by heating at 95°C 
for 5 min in Laemmli Buffer. The equivalent of 2.4 
oocytes was analysed by Western blotting. Brush 
Border Membrane Vesicles (BBMV) were 
prepared from whole mouse kidney using the Mg2+ 
precipitation technique as described elsewhere 
(14). Immunoblotting of the equivalent of 1 
oocytes or 20 μg of BBMVs was performed as 
described elsewhere (3). Primary antibodies were 
diluted (1:2000) for rabbit Affinity Purified (AP) 
anti-B0AT1 (3) / anti-XT2 (3) / anti-XT3 (3), 
(1:2000) for guinea-pig serum anti-Coll (antigen 
peptide : NH2-VQSAIRKNRNRINSAC-CONH2 
as in (15), Pineda, Berlin, Germany), (1:1000) for 
AP goat anti-mACE2 (R&D Systems, 
Minneapolis, USA), and (1:10000) for mouse anti-
mb-actin (Sigma, St Louis, USA). Secondary 
antibodies were diluted (1:5000) for ECLTM Anti-
rabbit IgG Horseradish Peroxidase linked fragment 
from donkey (Amersham Biosciences, Piscataway, 
USA), (1:10000) for Anti-guinea pig IgG 
Horseradish Peroxidase (Sigma) and (1:10000) for 
Anti-mouse IgG Alkaline Phosphatase Conjugate 
(Promega). Antibody binding was detected with 
Immobilon Western Chemiluminescent HRP or 
AP substrate (Millipore, Billerica, USA). 
Chemiluminescence was detected with a DIANA 
III camera (Raytest, Dietikon, Switzerland). For 
quantification relative to b-actin, signal intensity 
was quantified with the AIDA Image Analyzer 
(Raytest). 
Organ fixation - Mice were anesthetized with 
ketamine and xylazine (90 mg/kg body weight, 
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Narketan 10, Vétoquinol, Lure, France) and 
Xylazine (10 mg/kg body weight, Xylazin, Streuli, 
Uznach, Switzerland) intraperitoneally and 
perfused through the left cardiac ventricle with 
phosphate-buffered saline (PBS, 0.9% NaCl in 10 
mM phosphate buffer, pH 7.4) followed by a 
buffered paraformaldehyde solution (4%, pH 7), as 
previously described (16). Kidneys were then 
harvested, incubated overnight in 
paraformaldehyde solution, washed several times 
with PBS and stored in PBS-0.02% sodium azide 
at 4°C. Tissues were then mounted with Kryostat 
OCT (Medite, Nunningen, Switzerland), frozen in 
liquid propane and stored at - 80°C. 
Immunofluorescence - Immunofluorescence 
was performed as previously described (3). 
Primary antibodies were diluted (1:200) for rabbit 
Affinity Purified (AP) anti-mXT2 (3), (1:100) for 
AP goat anti-mACE2 (R&D), and (1:1000) for 
rabbit serum anti-mCollectrin  (antigen peptide : 
NH2-CDPLDMKGGHINDGFLT-CONH2 as in 
(15), Pineda). Secondary antibodies were diluted 
(1:500) for Alexa Fluor 594 donkey anti-rabbit 
IgG and Alexa Fluor 488 donkey anti-goat IgG 
(Molecular Probes, Invitrogen, Carlsbad, USA). 
For actin staining, Texas Red - X phalloidin 
(Molecular Probes) was diluted (1:500). Digital 
images were viewed using a Nikon Eclipse TE300 
epifluorescence microscope (Nikon Instruments 
Inc., Melville, USA) equipped with a DS-5M 
Standard CCD camera (Nikon) and acquired with 
NIS-Elements (Nikon). 
Telemetry measurement of blood pressure - 
Eight weeks old mice were anaesthetised (see 
Organ Fixation) and implanted with PA-C10 
transmitter (Data Sciences International (DSI), St. 
Paul, USA) through the carotid artery as 
previously described and following manufacturer 
information to place the pressure sensitive tip in 
the aortic arch (17,18). For analgesia purposes, 100 
μl of bupivacain hydrochloride 0.25% (Bucain, 
DeltaSelect GmbH Pfullingen, Germany) was 
injected directly in the wound at the end of the 
procedure and carprofenum (5mg/kg, Rimadyl, 
Pfizer, New York, USA) was injected 
subcutaneously every 12 h for 2 days. Twenty-four 
hours continuous measurements were recorded 
after 2 weeks of recovery with Dataquest ART 
version 3.1 and RespiRate (DSI). Systolic, 
diastolic and mean blood pressure, heart 
frequency, activity and respiratory rate were 
analysed separately for the light vs. dark phases 
and activity=0 vs. activity>0. To mimic tail-cuff 
manometry stress, mice were restrained during 20 
min in a perforated 50 ml Falcon tube, when the 
data was continuously measured. 
 
RESULTS 
 
Since XT2 has been shown to be associated in 
kidney proximal tubule with Coll (5), we tested the 
possibility that XT2 would be expressed 
functionally in X. laevis oocyte in the presence of 
this associated protein. XT2 was therefore co-
expressed in X. laevis oocytes with Coll and/or its 
homologue ACE2 and the uptake of L-isoleucine 
was tested. Unexpectedly, uptake of L-isoleucine 
was observed only when XT2 was co-expressed 
with ACE2, whereas no transport was observed 
when XT2 was expressed alone or together with 
Coll (Fig. 1A). Furthermore, co-expression of 
ACE2 and Coll with XT2 did not further increase 
the transport rate compared to XT2 + ACE2. 
The L-isoleucine transport induction upon 
ACE2 co-expression correlates with a slight 
increase of XT2 total protein in the oocytes (Fig. 
1B). Furthermore, co-immunoprecipitation of 
ACE2 from oocyte membranes using XT2 
antibody shows that ACE2 interacts with XT2 
(Fig. 1C). These results suggest that ACE2 acts as 
a chaperone for XT2 and increases its stability in 
X. laevis oocytes. This co-expression renders the 
measurement of XT2 transport function possible in 
an expression system for the first time. 
XT2 co-expression with ACE2 allowed the 
characterization of its transport selectivity, 
showing the transport of a broad range of neutral 
amino acids (A, M, V, I > G, S, L) (Fig. 2A). 
Concentration-dependence experiments with L-Ile 
and Gly revealed an apparent affinity of XT2 for 
these substrates (K0.5 0.21 mM and 0.53 mM, 
respectively) that is higher than that of B0AT1 
(Figs. 2B-C) (19). In contrast to B0AT1, but 
similarly to other members of the Slc6 family such 
as the GABA transporter GAT1 (Slc6a1), the 
transport of L-Ile by XT2 is not only Na+- but also 
Cl--dependant as well as pH-independent (Figs. 
2D-E). Because the transport activity of XT2 is not 
electrogenic, its function could not be tested using 
electrophysiological techniques (data not shown).  
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To assess the situation of the different partners 
in vivo, we first checked the localisation of XT2, 
Coll and ACE2 in mouse kidney. As previously 
shown, XT2 localises to the apical membrane in 
distal segments of the proximal tubule (S2,S3) and 
is not present in the initial S1 segment that begins 
at the glomerulus (3) (Fig. 3A). In contrast, ACE2 
and Coll are both localised along the entire 
proximal tubule, but with opposed gradients 
increasing towards the distal and proximal tubular 
ends, respectively (Fig. 3A). This shows that the 
main site of ACE2 expression coincides with the 
localisation of XT2, suggesting that XT2 may 
interact with ACE2 in the proximal tubule, 
additionally to its known interaction with Coll (5). 
To test the role of these two potential 
associated proteins on XT2 expression in vivo, we 
used ace2 and coll null mice. At the mRNA level 
in kidney, XT2 expression was unchanged in both 
coll (5) and ace2 null mice (Fig. 3B). However, 
Western blot analysis of kidney brush border 
membrane proteins showed that XT2 was absent in 
the coll-/y mice, in contrast to ace2-/y and wild-type 
mice (Figs. 3C-D). Immunofluorescence 
performed on kidney sections confirmed that XT2 
is lacking in coll-/y mice proximal tubule, whereas 
it is normally expressed in ace2-/y as in wild-type 
control mice (Figs. 3E-F). These results confirm 
that the partner of XT2 in mouse kidney is indeed 
Coll and not ACE2, despite the fact that the 
expression gradient of Coll along the proximal 
tubule is opposed to that of both XT2 and ACE2 
and that Coll unlike ACE2 does not allow XT2 
expression in X. laevis oocytes. 
To verify and examine the role of XT2 as an 
amino acid transporter more in detail, we re-
analysed the xt2 null mouse model (2) after more 
than 10 generations of backcrossing in C57BL/6 
background. To evaluate whether the lack of XT2 
induces compensatory changes, we examined the 
expression of the Slc6 family members B0AT1 and 
XT3 and of the associated proteins ACE2 and Coll 
at the mRNA and protein levels in xt2-/- mice but 
observed no difference with wild-type littermate 
controls (Supplemental Figs. 1A-B). 
To evaluate the impact of the loss of XT2 on 
the whole animal, we monitored food and water 
intake as well as urine and feces output in 
metabolic cages, but there were no differences in 
the measured parameters between the xt2+/+ and 
xt2-/- mice (Supplemental Table 1).  Analysis 
of plasma amino acids only suggested a slight but 
statistically not significant decrease of glycine (G) 
and L-arginine (R) in the xt2-/- mice as compared 
to the xt2+/+ mice (Fig. 4A). A massive loss of 
glycine in the urine of the xt2-/- mice was 
confirmed and the loss of other neutral amino 
acids, notably L-glutamine (Q), was observed (Fig. 
4B). However, calculating an approximated 
fractional excretion (based on an estimated 
glomerular filtration rate of 150 μl/min in females 
and 240 μl/min in males (20)) L-glutamine was 
only fractionally excreted to 2.20%, whereas 
glycine and L-methionine (M) were fractionally 
excreted up to 51.37% and 33.41% in the xt2-/- 
mice, respectively (Table 1). These results show 
that despite aminoaciduria, these mice do not 
exhibit any compensatory mechanisms, implying 
that the normal diet readily provides excessive 
amounts of amino acids. The urinary peak 
corresponding to L-arginine could unfortunately 
not be distinguished from that of taurine, 
preventing the evaluation of L-arginine loss in xt2 
null mice. Challenging xt2 null animals with a low 
protein diet (<0.5% crude protein) didn’t induce 
any additional difference in the metabolic cages 
parameters measured between xt2 null and wild-
type mice (Supplemental Table 1). 
In the original study, xt2 null mice displayed, 
compared to wild-type littermates, a surprising 
elevation of blood pressure as measured by tail 
cuff manometry. This difference was then 
abolished when drinking water was supplemented 
with glycine (0.1 g/ml) (2). The blood pressure of 
xt2 null mice was now retested using mice 
backcrossed more than 10 times into C57BL/6 
background and using telemetry (Datasciences). 
The measurements showed no differences in blood 
pressure between the xt2-/- and xt2+/+ mice during 
the light phase when mice were not active (Fig. 
5A). Similar results were obtained during the light 
and dark phases, whether the mice were active or 
not (data not shown). To test whether the 
previously measured increase in blood pressure 
was provoked by the stress of the tail cuff 
manometry method, telemetry measurements were 
repeated while physically restraining the mice. 
Submitting the animals to this stress provoked a 
higher mean blood pressure in xt2-/- mice than in 
wild-type litter-mates (130.8 ± 0.89 mmHg versus 
125.3 ± 1.40 mmHg), and also a higher respiratory 
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rate (Fig. 5B). This suggests an increased stress-
induced reaction possibly involving a 
dysregulation of the sympathetic nervous system in 
xt2-/- mice. 
 
DISCUSSION 
 
The first aim of this study was to directly 
characterise the function of the orphan transporter 
XT2 in the X. laevis oocytes expression system 
using its in vivo associated protein Coll. However, 
not Coll but only its homologue ACE2 supported 
the functional surface expression of XT2 in X. 
laevis oocytes such that its transport function of 
neutral amino acids expected from its homology 
with B0AT1 could be measured. This raised the 
suggestion that ACE2 might interact with XT2 in 
mouse kidney in addition to Coll. However, our 
experiments with the ace2 and coll null mice 
confirmed that the in vivo partner of XT2 is Coll 
and not ACE2. Indeed XT2 expression and 
localisation in the proximal kidney tubule was 
normal in ace2 null mice and absent in coll null 
mice. This observation suggests the possibility that 
the rising implication of ACE2 as a key player of 
the renin-angiotensin system during evolution 
induced the appearance of Coll by duplication in 
order to take over its role in amino acid transport. 
It is however not clear why the restriction of 
functional XT2 association with ACE2 or Coll is 
just opposite in X. laevis oocytes as compared to 
the in vivo situation in kidney. Further experiments 
will be required to identify potential additional 
cell-specific players that account for this 
difference. 
The functional expression of XT2 together 
with ACE2 in oocytes allowed the long sought 
characterisation of the function of this orphan 
transporter. Interestingly, its broad transport 
selectivity for neutral amino acids is clearly 
different from that of B0AT1. Particularly, whereas 
beta-branched amino acids are very good 
substrates for XT2, as it is the case for B0AT1, 
aromatic amino acids are apparently less 
efficiently transported. Importantly, L-Ala, L-Met, 
Gly, L-Ser and L-Cys are also efficiently 
transported. 
In contrast to B0AT1 that displays a Na+-
dependant electrogenic neutral amino acid 
transport, XT2 is shown here to display a transport 
mode that is not only Na+, but also Cl--dependant 
and non-electrogenic with an affinity for its 
preferred substrates that is higher than that of 
B0AT1. In that sense, the axial arrangement of 
XT2 that follows B0AT1 along the proximal tubule 
recalls the analogous sequential arrangement of 
low and high affinity glucose and peptide 
transporters SGLT2 and 1 and Pept1 and 2, 
respectively. 
To correlate the measured in vitro function of 
XT2 with its in vivo function we re-analysed the 
xt2 null mouse model. As the knock-out mice 
didn’t display compensatory changes of other 
amino acid transporters of the SLC6 cluster, or of 
associated proteins, we hypothesise that the 
urinary phenotype of xt2 null mice is essentially 
due to the absence of XT2. In accordance to the in 
vitro results we measured a broad aminoaciduria. 
Strikingly, there was not only a substantial loss of 
glycine (60-fold higher than in xt2+/+) but also of 
L-glutamine (20-fold) and of all other neutral 
amino acids (Fig. 4). XT2 thus appears to be 
required for reabsorbing the leftover tubular amino 
acids that have not been reabsorbed in the early 
proximal kidney tubule segments by B0AT1 or the 
amino acids that would eventually backleak into 
the late proximal tubule segments through the 
paracellular route (21). Additionally, XT2 might 
also be required for the reabsorption of neutral 
amino acids that the luminal heterodimeric cystine 
and cationic amino acids transporter b0,+AT-rBAT 
releases in exchange for its uptake substrates in the 
tubular lumen. Thereby XT2 would interfere with 
L-arginine metabolism and nitric oxide (NO) 
synthesis (22). This latter hypothesis could be an 
explanation for the slightly decreased L-arginine 
plasma level and the tendency for elevated blood 
pressure observed in xt2 null mice.  
Interestingly, XT2 had originally been 
identified in rat kidney as a renal osmotic stress-
induced transcript (ROSIT) (23). However, the 
experiments that we performed in mice could not 
verify such a regulation (E. Romeo and F. Verrey, 
unpublished results). This is either due to a species 
difference or to the less drastic conditions that we 
used which might not have been sufficient to 
trigger this regulation. 
In their original description, xt2 null mice 
displayed a significantly elevated blood pressure 
(2). This was however not observed in the present 
study after backcrossing these mice 10 times in a 
C57BL/6 background and using a telemetry system 
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for the blood pressure measurements. Previous 
reports have already evidenced discrepancies 
between tail cuff manometry and telemetric blood 
pressure measurements and also highlighted the 
importance of the genetic background. In 
particular, the original xt2 null mouse had Sv129 
genetic background, a strain that contains two 
renin genes and the renal blood flow of which was 
suggested to be more sensitive toward NO than 
that of C57BL/6 mice (24). We could however 
observe in the present study a stress-sensitive 
hypertension and a stress-induced increase in 
respiratory rate in xt2 null mice, suggesting a 
possible impact of the lack of this transporter on 
regulatory functions of the sympathetic nervous 
system. Interestingly, plasma L-arginine of xt2-/- 
mice was slightly lower than in the xt2+/+ mice and 
L-arginine is the precursor of nitric oxide that, 
when released by endothelial cells, leads to 
vasodilation. Slightly lower circulating and renal 
levels of L-arginine might therefore induce 
susceptibility to an increase in blood pressure (25). 
The role of XT2 in human seems to be limited 
since SLC6A18 has not been found associated 
with iminoglycinuria (R. Kleta, personnal 
communication). Furthermore, a frequent SNP that 
leads to a stop codon in SLC6A18 has not been 
linked to increased blood pressure (4). However, it 
is not excluded that the individual variability in 
stress-induced blood pressure increase could be 
linked to the function of this renal neutral amino 
acid transporter. 
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† Camargo, S.M.R., Singer D., Makrides V., Katja Huggel K., Pos K.M., Wagner C.A., Kuba K., 
Danilczyk U., Skovby F., Kleta R. Penninger J.M., and Verrey F. Tissue-specific amino acid transporter 
partners ACE2 and Collectrin differentially interact with Hartnup mutations. Submitted. 
 
ACE2 :  Angiotensin-converting enzyme 2 
Coll : Collectrin (Tmem27) 
BBMV : Brush border membrane vesicles 
HPRT : Hypoxanthine Guanine Phosphoribosyltransferase 
GAPDH : Glyceraldehyde 3-phosphate dehydrogenase 
 
 
FIGURE LEGENDS 
 
Fig. 1. XT2 and ACE2 functional interaction in vitro. A. Co-expression of ACE2 but not of Coll supports 
the function of XT2 in X. laevis oocytes. X. laevis oocytes were injected with 10 ng of each cRNA and 
incubated for 6 days. Na+-dependent uptake of L-Ile 0.1 mM (10 min) was assayed. The data represent 16-
24 oocytes from 2-4 independent experiments. Bars indicate mean value ± SEM. *** P<0.001. B. Total 
membrane proteins of X. laevis oocytes were analysed by Western blot using anti-XT2 antibody. Kidney 
brush border membrane vesicles (BBMV) were used as control. C. Total membranes of X. laevis oocytes 
were used for immunoprecipitation with an anti-XT2 antibody and immunocomplexes were analysed by 
Western blot with anti-ACE2 antibody. 
 
Fig. 2. Transport selectivity and kinetics of XT2 co-expressed with ACE2. A. Substrate selectivity of XT2 
co-expressed with ACE2 in X. laevis oocytes. Na+-Cl--dependant uptake selectivity of L-AA (0.1 mM) 
was assayed for 10 min. Amino acids are abbreviated with the single letter code. B, C. Concentration 
dependence of the XT2-ACE2 mediated transport in oocytes. Curves corresponding to Michaelis-Menten 
kinetics were fitted to Na+-Cl--dependant uptake of L-Ile (B) and Gly (C). Data represent means of 18-39 
oocytes ± SEM from 3-5 independent experiments. D. Transport induced by XT2 co-expressed with 
ACE2 is Na+- and Cl--dependant. Data are means of 13-16 oocytes ± SEM from two independent 
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experiments. E. Transport of L-Ile was not influenced by pH. The transport of L-Ile was assayed in the 
presence of Na+ and Cl- at different pH’s. Bars and points indicate mean value from 8 oocytes ± SEM. 
 
Fig. 3. Lack of XT2 in coll-/y but not in ace2-/y mouse kidney. A. Immunofluorescence of wild-type kidney 
co-labelled with XT2 and ACE2, and on a consecutive section co-labelled with Coll and Actin. G : 
glomerulus. B. Real time RT-PCR of XT2 and Coll on ace2+/y and ace2-/y total kidney RNA. Bars indicate 
mean value ± SEM, n=3 mice per genotype. C, D. Kidney brush border membrane vesicles (BBMV) (20 
μg) from coll+/y and coll-/y mice (C) and ace2+/y and ace2-/y mice (D) were analysed by Western blot using 
antibodies against XT2, Coll (with a specific signal at 42 kDa, see supplemental data), ACE2, and β-actin 
(βa). Immunofluorescence of coll-/y kidney co-labelled with XT2 and ACE2 (E), and ace2-/y kidney 
labelled with XT2 and on a consecutive section with Coll (F). As shown also by Western blot in C, D, 
XT2 expression is lacking in kidney of coll null mice, whereas it is expressed in ace2 null mice. 
 
Fig. 4. The xt2 null mice have increased levels of neutral amino acids in urine, and a slight but not 
significant decrease of plasma glycine (G) and L-arginine (R). Plasma (A) and urine (B) of xt2+/+ and xt2-/- 
mice was deproteinized and analysed by HPLC. Bars indicate mean values ± SEM, n=7 (A) and n=6 (B) 
mice per genotype. *P<0.05, ** P<0.01, *** P<0.001. ND: not determined. 
 
Fig. 5. The xt2 null mice display a stress-induced increase of blood pressure and respiratory rate. The 
xt2+/+ and xt2-/- mice were implanted with blood pressure telemetry sensors (DSI). Mean pressure, pulse 
pressure and respiratory rate (RCPM : Respiratory Cycle Per Minute) of xt2+/+ and xt2-/- mice during the 
light period, when the mice were not active (A) or during a 20 min physical restrain stress (B). Bars 
indicate mean values ± SEM, n=7 mice per genotype. *P<0.05, ** P<0.01. 
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 Table 1. Fractional urinary amino acid excretion  
1Fractional excretion was calculated using an estimate of the glomerular filtration rate of 150 μl/min in 
females and 240 μl/min in males (20), the measured amino acid concentrations in plasma and urine and 
the volume of urine excreted over 24 h.  
2ND: not determined. 
 
 
1Fractional       
excretion (%) 
 xt2+/+ xt2-/- 
fold 
change 
G 0.53 51.37 96.25 
A 0.59 4.49 7.60 
V 0.33 3.50 10.75 
L 1.23 11.71 9.50 
I 2.30 8.97 3.90 
M 5.00 33.41 6.68 
S 0.47 6.66 14.07 
T 1.04 7.33 7.06 
C ND ND ND 
P 0.33 0.59 1.79 
N 2.91 6.76 2.33 
Q 0.11 2.94 26.72 
F 0.39 5.87 15.21 
Y 0.34 2.14 6.38 
W 1.97 4.24 2.16 
K 1.58 2.98 1.88 
R 2ND ND ND 
H 1.74 9.66 5.56 
D 2.62 4.12 1.57 
E 11.46 16.03 1.40 
 
 
 
170
130
95
IP: XT2  
XT2
WB: ACE2
+
+
+
XT2
ACE2
Coll
+ +
+
+
+
+
+
+
+
+
oocytes
72
55
40
B
B
M
V
XT2
ACE2
Coll
+ +
+
+
+
+
+
+
+
+
100
200
0
A
B
C
Figure 1
L-
Ile
 
(N
I s
u
bs
tr
ac
te
d)
 
pm
o
l/h
o
u
r/o
o
cy
te
ns
*** ns
ACE2+
11
Figure 2
0.00 0.25 0.50 0.75 1.00 1.25
0
100
200
300
400
500
L-Ile (mM)
XT2
XT2+ACE2
ACE2
A
B C
D E
0
100
25
-25
50
75
G A V L I M S T C P N Q F Y W K R H D E
pm
o
l/h
o
u
r/o
o
cy
te
(N
I s
u
bs
tr
ac
te
d)
Vmax  477 4  p / 4 mol hour
K
.0 5   0. 1 2 0.06 mM
±
±
0 1 2 3 4
0
50
100
150
200
250
Gly (mM)
pm
o
l/h
o
u
r/o
o
cy
te
(N
I s
u
bs
tr
ac
te
d)
pm
o
l/h
o
u
r/o
o
cy
te
(N
I s
u
bs
tr
ac
te
d)
Vmax  226  26 p ol/ ourm h
K
.0 5   0. 3 5 0. 7 mM1  
±
±
-50
0
50
100
150
200
250
-25
0
25
50
75
100
125
L-
Ile
 
(N
I s
u
bs
tr
ac
te
d)
 
pm
o
l/h
o
u
r/o
o
cy
te
L-
Ile
 
(N
I s
u
bs
tr
ac
te
d)
 
pm
o
l/h
o
u
r/o
o
cy
te
NaCl +-Na --Cl 6.5 7.4 8.0
ns
12
Figure 3
XT2
ACE2
Coll
Actin
XT2
ACE2
ace2       and  coll
XT2
ace2
Coll
55
36
βa
coll +/y -/y
72
95
55
130
ACE2
XT2
XT2
Coll
A B
C D
E F
+/y +/y
ace2+/y ace2 -/y
XT2
m
R
N
A 
ab
u
n
da
n
ce
(re
la
tiv
e 
to
 
H
PR
T)
0
1
3
2
4
6
5
ace2+/y ace2 -/y
Coll
m
R
N
A 
ab
u
n
da
n
ce
(re
la
tiv
e 
to
 
H
PR
T)
0
10
30
20
40
βa
βa
βa
-/y
ace2
-/y
coll
G
G G
72
55
+/y -/y
G
13
Figure 4
A
*
***
**
***
***
***
***
***
***
***
***
**
**
*ND ND
Ur
in
e 
am
in
o
 
ac
id
s 
(m
M
)
0
5
10
20
40
60
G A V L I M S T C P N Q F Y W K R H D E
Pl
as
m
a 
am
in
o
 
ac
id
s 
(µM
)
µ
0
300
100
200
400
1000
2000
G A V L I M S T C P N Q F Y W K R H D E
ND
B
xt2+/+
xt2 -/-
ns
ns
14
Figure 5
**
*
B
A
xt2 xt2 -/-
M
ea
n
 
Pr
es
su
re
 
(m
m
H
g)
+/+
2090
100
25
Pu
ls
e 
Pr
es
su
re
 
(m
m
H
g)
30
M
ea
n
 
Pr
es
su
re
 
(m
m
H
g)
120
130
35
25
30
Pu
ls
e 
Pr
es
su
re
 
(m
m
H
g)
250
275
300
R
es
pi
ra
to
ry
 
R
at
e 
(R
CP
M
)
xt2 xt2 -/-+/+
xt2 xt2 -/-+/+ xt2 xt2 -/-+/+ xt2 xt2 -/-+/+
150
175
200
R
es
pi
ra
to
ry
 
R
at
e 
(R
CP
M
)
xt2 xt2 -/-+/+
15
SLC6A18 is neutral amino acid transporter B0AT3 
 
16 
Orphan transporter SLC6A18 is renal neutral amino acid transporter B0AT3  
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Supplemental Table 1. Summary of metabolic cage and urine data from male and female mice. 
Male and female mice were fed a normal protein diet (A. 18.5 %, 2 d), a low protein diet (B. <0.5 %, 2 d) 
or were deprived of water (C. 24 h) A. Males n=9, females n=8, total n=17. B. Males n=4, females n=5, 
total n=9. C. Males n=5, females n=3, total n=8. Data indicate means ± SEM. Urinary excretion was 
normalized to creatinine (crea). BW: body weight. ND: not determined. 
 
 ANormal protein diet (2 d) BLow protein diet (2 d) CWater deprivation (24 h) 
 xt2+/+ xt2-/- xt2+/+ xt2-/- xt2+/+ xt2-/- 
Males body weight 
(g) 25.28±0.39 25.62±0.51 22.98±0.50 23.73±0.33 23.36±0.19 23.08±0.75 
Females body 
weight (g) 21.65±0.43 21.65±0.39 20.28±0.09 20.44±0.35 19.17±0.82 18.93±0.65 
Males and females :      
Food (g/g BW) 0.155±0.0075 0.158±0.008 0.142±0.005 0.147±0.003 0.110±0.010 0.113±0.005 
Water (ml/g BW) 0.24±0.02 0.22±0.01 0.45±0.05 0.39±0.05 0 0 
Feces (g/g BW) 0.056±0.004 0.053±0.005 0.018±0.004 0.018±0.002 0.0322±0.003 0.0310±0.002
Urine (ml/g BW) 0.031±0.005 0.039±0.005 0.200±0.026 0.162±0.023 0.012±0.003 0.018±0.003 
Creatinine (mM) 5.44±0.42 5.19±0.34 1.40±0.17 1.39±0.17 5.82±0.61 6.15±0.43 
Osmolality 
(mOsm/kg) 3266±209 3079±14 457.3±44.2 509.8±47.0 4680±356 4540±377 
pH 6.23±0.07 6.28±0.12 6.22±0.14 6.27±0.06 ND ND 
Na+/crea 33.08±4.08 38.44±4.71 81.93±5.20 122.9±21.4 44.11±7.38 41.91±8.60 
K+/crea 112.9±13.0 122.2±14.8 58.02±5.19 78.99±11.29 127.8±2.285 111.1±11.66 
Ca2+/crea 0.97±0.24 1.08±0.22 3.15±1.193 2.26±0.25 0.36±0.07 0.28±0.07 
Mg2+/crea 10.25 ± 1.11 11.44 ± 1.56 8.10 ± 0.73 10.19 ± 1.56 8.76 ± 0.50 9.52 ± 0.73 
Cl-/crea 58.78 ± 1.90 60.15 ± 2.55 83.54 ± 2.72 100.4 ± 12.12 135.9 ± 21.12 154.5 ± 26.59 
PO42-/crea 9.03 ± 0.64 10.05 ± 1.23 28.62 ± 1.61 30.56 ± 1.58 31.50 ± 5.24 27.18 ± 4.34 
SO42-/crea 14.34 ± 0.87 14.13 ± 0.74 4.82 ± 0.48 4.83 ± 0.38 24.82 ± 2.71 28.62 ± 5.06 
 
 
Supplemental Fig. 1. Absence of compensatory regulation of other renal SLC6 amino acid transporters or 
associated proteins in xt2 null mice. A. Real time RT-PCR of B0AT1, XT3 (Slc6a20a) and SIT1 
(Slc6a20b) on ace2+/y and ace2-/y total kidney RNA. Bars indicate mean value ± SEM, n=2 mice per 
SLC6A18 is neutral amino acid transporter B0AT3 
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genotype. B. Western blot analysis on kidney BBMV (20 μg) from xt2+/+ and xt2-/- mice using antibodies 
against B0AT1, XT3, ACE2, Coll, and β-actin (βa). 
 
Supplemental Fig. 2. Specificity of the guinea-pig serum anti-Coll was tested on coll+/y and coll-/y 
BBMVs with and without deglycosylation (PNGase F). A specific signal is detected around 40 kDa. 
Hydrolysis of Asn-oligosaccharides was carried out using endo-beta-N-acetylglucosaminidase F enzyme 
(PNGase F) (New England Biolabs, USA). 
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9. Physiological impact of ACE2 loss on amino acid 
transport 
 
 
9.1. Rationale 
 
As presented in section 7.2, ace2 null mice have a defect in protein expression of the neutral 
amino acid transporter B0AT1 in the brush border of the small intestine. The following section 
evaluates the impact of such a defect on mouse development. The phenotype reported in 
this section is presumably only partly due to the defect of intestinal B0AT1 amino acid 
transporter. For instance, the control of the proline transporter SIT1 (Slc6a20) by ACE2 is not 
yet clear and requires further investigation. Furthermore, possible cardiac and hypertensive 
phenotypes and increased Ang II levels might additionally play a role on mouse 
development, although  their effects have been described in older mice (6 months). 
 
 
9.2. Material and Methods 
 
Animals 
The ace2 wild-type and knock-out mice were housed in standard conditions and fed a 
standard diet. Generation of the knock-out mice was described elsewhere (Crackower et al, 
2002). All procedures for mice handling were according to the Swiss Animal Welfare laws 
and approved by the Kantonales Veterinäramt Zürich. 
 
Metabolic cages 
Animals were adapted to metabolic cages (Tecniplast, Buguggiate, Italy) for 3 days before 
data collection, where they had free access to standard mouse diet (18.5% crude protein, 
Kliba-Nafag, Kaiseraugst, Switzerland) and drinking water. Daily food / water intake, urine / 
feces output and body weights were measured. Urinary pH was measured using a pH 
microelectrode (691 pH-meter, Metrohm). Urinary creatinine was measured by the Jaffe 
method (Seaton & Ali, 1984). Urinary and plasma urea were measured using the diacetyl 
monoxime method (Wybenga et al, 1971). Urinary electrolytes (Na+, K+, Ca2+, Mg2+, Cl-,  
SO42-) were measured by ion chromatography (Metrohm ion chromatograph, Herisau, 
Switzerland). 
Mouse blood was collected by decapitation and 1 ul of heparin-Na+ 25000 I.E./5 ml (B. 
Braun, Melsungen, Germany) was added. Plasma was collected after centrifugation at 6000 
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g and 4°C. Ice-cold methanol deproteinization of the plasma was performed as described 
elsewhere (Suresh Babu et al, 2002). Hundred microliters of deproteinised sample was dried 
and resuspended in 45 ul of borate buffer. Samples were then derivatized using AccQ Tag 
(Waters, Milford, USA) and analyzed on an Acquity UPLC (Waters) according to the 
manufacturers instructions by the Functional Genomics Center Zurich (FGCZ) (Cohen & De 
Antonis, 1994). 
One microliter mouse urine collected over 24 h was diluted up to 100 ul by 50 mM HCl 
containing the internal standards norvaline and sarcosine in a concentration of 50 pmol/ul. 
The solutions were centrifuged, and transferred into new hydrolysing tube. One microliter 
was injected for pre-column derivatization with ortho-phthaldialdehyde (OPA) and analyzed 
on an Amino Quant amino acid analyzer (Agilent Technologies GmbH, Böblingen, Germany) 
at the Functional Genomics Center Zurich (FGCZ). 
 
Growth Curve 
Pups from ace2+/- x ace2+/y breedings weights were recorded starting one day after birth. 
Identification was possible by marking the pups’ body using a Securiline alcohol-resistant lab 
marker (Precision Dynamics Corporation, San Fernando, USA). The tail was similarly marked 
when fur appeared on the body. At day 21, pups were weaned from the mother, separated 
by sex and biopsies were sampled for genotyping.  
 
Statistics 
Data are presented as means ± standard error of the mean (SEM). Analyses were done by 
running the GraphPad Prism 4.0 software (GraphPad). Between-group comparisons were 
performed by Student's unpaired t-test. For comparisons of weight differences between 
ace2+/y and ace2-/y during the growth experiments, the average weight was calculated for the 
genotype for each litter and analysed by a paired t-test. Statistical significance was accepted 
at P < 0.05. 
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9.3. Results 
9.3.1. Lack of ACE2 affects plasma amino acids levels 
 
We first measured plasma amino acid levels of ace2 null mice to evaluate how amino acid 
homeostasis was affected by loss of intestinal B0AT1. Decrease of plasma amino acid levels 
did not cover the whole range of B0AT1 neutral amino acids substrates but was specific for 
glycine (G) and L-tryptophan (W). Surprisingly, this was accompanied by an increase of L-
lysine (K) (Figure 1). 
To estimate amino acid transporter function in the kidney of ace2 null mice, we calculated the 
expected fractional excretion rates of amino acids in the urine using an estimate of 
glomerular filtration rate. As suggested by the normal expression levels of B0AT1 in kidney 
brush border, fractional excretion of amino acids in the urine were not significantly modified 
(Table 1). 
We have previously shown that the Na+-dependant transport of L-isoleucine is absent in 
isolated intestine rings of ace2-/y mice (Camargo et al, in press). Since L-isoleucine is an 
essential amino acid, its transport in a di-/tri-peptide form through peptide transporter PepT1 
seems to sufficiently compensate for lack of B0AT1. The mRNA expression levels of PepT1 
were however not increased (data not shown). 
 
 
 
 
 
 
 
Figure 1. The ace2 null male and female mice have decreased plasma levels of L-
tryptophan (W) and glycine (G). Plasma of ace2+/y n=11 and ace2-/y n=6 mice was 
deproteinized and analysed by HPLC. Mean ± SEM. * P<0.5, ** P<0.01 
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1Fractional excretion (%) 
 2ace2+/y ace2-/y fold change
G 0.73 0.51 0.69 
A 0.43 0.69 1.61 
V 0.13 0.07 0.51 
L 0.45 0.25 0.56 
I 0.39 0.15 0.37 
M 1.61 1.19 0.74 
S 2.48 1.77 0.72 
T 0.57 0.35 0.61 
P 1.71 1.13 0.66 
N 2.65 1.98 0.75 
Q 0.32 0.32 1.00 
F 0.87 0.67 0.77 
Y 0.61 0.49 0.80 
W 0.30 0.39 1.30 
K 0.10 0.09 0.88 
R 0.76 0.53 0.69 
H 1.25 1.11 0.89 
D 3ND ND ND 
E 4.05 3.61 0.89 
 
Table 1. Fractional urinary L-amino acid excretion  
1Fractional excretion was calculated using an estimate of the glomerular filtration rate of 240 
ul/min in males (Qi et al, 2004), the measured amino acid concentrations in plasma and urine 
and the volume of urine excreted over 24 h. 2Males n=5. 3ND: not determined. 
 
 
9.3.2. Lack of ACE2 affects mouse development 
 
To test whether the disturbances in plasma amino acid homeostasis affected mouse 
development, ace2 null mice and wild-type littermates were placed in metabolic cages. This 
allowed measurement of basic parameters such as food and water intake as well as urine 
and faeces output. Urine and plasma were collected and analysed further (Table 2). Body 
weight (BW) was slightly but significantly lower in ace2 null mice, when compared to their 
wild-type littermates. 
Disturbances in ion excretion (higher excretion of Ca2+, Mg2+ and PO43- and lower excretion of 
SO42- in ace2 null mice) and pH might be linked to differences in transporters expression at 
the small intestine membrane or to Ang II levels. However, Na+ levels which are more directly 
linked to blood pressure control were found to be normal. It was however not possible to 
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measure plasmatic ion levels preventing educated guesses regarding the origin of the 
disturbance. 
Water consumption, when related to the body weight was slightly higher in ace2 null mice 
when compared to wild-type littermates, which could be due to increased circulating Ang II 
levels that stimulate thirst and prevent water loss. However, this might be an artefact as urine 
volume is not significantly affected. 
 
 1ace2+/y 2ace2-/y  
3BW (g) 25.87 ± 0.23 24.90 ± 0.33 * 
Food (g) 3.80 ± 0.18 3.83 ± 0.14  
Water (g) 5.02 ± 0.33 5.74 ± 0.29  
Urine (g) 1.20 ± 0.12 1.25 ± 0.12  
Feces (g) 1.38 ± 0.10 1.36 ± 0.10  
    
/ BW (g)    
Food 0.147 ± 0.007 0.154 ± 0.005  
Water 0.194 ± 0.012 0.231 ± 0.012 * 
Urine 0.046 ± 0.004 0.050 ± 0.005  
Feces 0.053 ± 0.004 0.054 ± 0.003  
    
Urinary parameters    
Anions (umol/24h)    
Cl- 309.6 ± 14.17 304.7 ± 23.65  
PO43- 114.9 ± 8.60 146.8 ± 9.81 * 
SO42- 70.51 ± 4.71 48.19 ± 3.06 *** 
Cations (umol/24h)    
Na+ 164.6 ± 14.41 181.8 ± 16.96  
K+ 504.9 ± 33.03 522.0 ± 42.12  
Ca2+ 2.21 ± 0.45 5.96 ± 0.98 ** 
Mg2+ 39.72 ± 2.14 67.65 ± 5.55 *** 
    
Osmolality (mOsm/kg) 3600 ± 422.6 3716 ± 389.6  
pH 6.26 ± 0.05 6.01 ± 0.03 *** 
Creatinine (umol/24h) 6.31 ± 0.57 4.69 ± 0.53  
Urea (mmol/24h) 2.07 ± 0.17 2.23 ± 0.10  
    
Plasma parameters     
Urea (mM) 9.01 ± 0.23 10.01 ± 0.33 * 
 
 
Table 2. Summary of metabolic cages and urine data from 8 weeks old male mice: 
1ace2+/y n=10, 2ace2-/y n=11. 3BW: body weight. Mean ± SEM. * P<0.05, ** P<0.01, *** 
P<0.001. 
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The normal food consumption together with the decreased weight of the of ace2 null mice 
suggests that defect in amino acid transport is compensated for, and does not affect body 
weight homeostasis in the adult. To test whether this decreased weight already originates at 
birth or only later during development, ace2 male pups from 4 ace2+/- x ace2+/y breeding pairs 
were weighed from day 1 to day 47. This shows that ace2 null mice and wild-type littermates 
have similar weights at birth and that ace2 null mice thrive but with a delayed weight gain 
after weaning starting at day 23. The lower weight of ace2-/y was maintained until day 47 
(Figure 2). The slower weight gain of ace2 null mice occurs after weaning of the pups, 
leading to a diet switch from mother milk to pellet food. This might be linked to a later 
expression of peptide transporters during development though one can not exclude the 
impact of ACE2 defect as a key enzyme in the RAS. 
 
 
 
Figure 2. The ace2 null mice lower weight originates after weaning. The ace2 mice were 
weighed after birth and showed a slower weight gain after weaning. ace2+/y n=8, ace2-/y  n=6. 
Mean ± SEM. * P<0.05; ** P<0.01; *** P<0.001. Mouse weight was analysed by paired t-test 
of the genotype weight average of each litter. 
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9.4 Discussion 
 
We have determined that the enzyme of the renin-angiotensin system (RAS) ACE2 is critical 
for the expression of the neutral amino acid transporter B0AT1 at the luminal membrane of 
small intestine epithelial cells and, by co-immunoprecipitation, that they interact at the 
membrane. The extent of this interaction is not clear as we do not know at which point in the 
sorting process it starts, whether all B0AT1 molecules still interact with ACE2 once they reach 
the membrane, and/or whether ACE2 regulates B0AT1 function at the membrane. 
The aim of this last section was to characterise the ace2 null mice in a broader physiological 
context. The phenotype of the ace2 null mice turned out to be relatively discrete when 
compared to wild-type mice: 1) The plasma levels of L-tryptophan and glycine are decreased 
and that of L-lysine and urea increased whereas the renal amino acid fractional excretion 
rates are normal. 2) Additional disturbances in urinary pH and ions were observed. 3) A 
slower weight gain of ace2 null mice after weaning led to a lower weight at 8 weeks. 
These different points are addressed in the following sections. 
 
 
Plasma neutral amino acids are compensated by PepT1 absorption 
 
L-isoleucine (L-Ile) is an essential amino acid that cannot be synthesised by the body. As 
ace2 null mice do not display Na+-dependant transport of L-Ile, this amino acid probably 
enters the enterocytes as di- and tri-peptides through PepT1, thereby compensating plasma 
L-Ile levels. A way to verify and bypass this compensation would be to replace protein amino 
acids from the diet with free amino acids and measure the difference between ace2 null and 
wild-type mice. Another similar approach would be to inhibit PepT1 with Lys[Z(NO(2))]-Pro, 
which has only been tested in vitro (Knutter et al, 2001) or cross ace2 null mice to pepT1 
knock-out mice (Hu et al, 2008). The apical exchanger b0,+AT-rBAT remains an alternative 
pathway for L-Ile uptake. 
 
Plasma amino acid homeostasis disturbances observed in ace2 null mice may, next to small 
intestine transporter defects, additionally originate from dysfunctions present in other organs 
at the transporter or at the metabolic level. We have shown that kidney amino acid transport 
is not grossly modified, but liver, muscle and brain still remain to be investigated. 
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Plasma L-tryptophan 
 
Though the affinity of B0AT1 for the essential amino acid L-tryptophan is weaker than for 
other large neutral amino acids in vitro (~25%), the decreased L-tryptophan level in ace2 null 
mice is interesting in regards to Hartnup disorder. L-tryptophan indeed serves as a precursor 
for the synthesis of serotonin, melatonin and niacin (vitamin B3, nicotinic acid) and its lack 
might cause Hartnup disorder symptoms that accompany aminoaciduria in certain subjects 
such as pellagra-like rashes and cerebellar ataxia (Milne, 1969).  
Pellagra is a disease characterised by dermatosis, diahrrea, and dementia that manifests in 
situations of inadequate dietary niacin intake or lack of its precursor L-tryptophan (Pitche, 
2005). Niacin is implicated in the synthesis of nicotinamide dinucleotide (NAD) and 
nicotinamide dinucleotide phosphate (NADP) that are necessary for oxido-reduction 
reactions, the citric acid cycle and fatty acid synthesis. Niacin defect affects more extensively 
the brain that has high energy demands, and tissues undergoing high cellular renewing rates 
like the skin and the intestine. Niacin supplementation has been shown to be effective to 
treat the ataxia in certain Hartnup disorder cases (Camargo et al, 2008). 
The tmem27 knock-out mice have defective expression of B0AT1 in kidney but not in small 
intestine and also do not exhibit modified plasma levels of L-tryptophan. Since the non-
aminoaciduria symptoms of Hartnup disorder probably originate from the defect of intestinal 
B0AT1 transport, ace2 knock-out mice might represent an appropriate model. However, 
Hartnup-related symptoms did not appear in ace2 null mice possibly due to compensation by 
PepT1 and because of sufficient niacin levels in the diet (60-70 mg/kg diet). These symptoms 
could eventually be exacerbated by subjecting the mice to a niacin-free diet. 
 
 
Plasma Glycine 
 
B0AT1 has an intermediate affinity for glycine (~50% of L-Leu) (Camargo et al, 2005). 
Glycine is essential for creatinphosphate synthesis that supplies muscles with energy by 
replenishing ATP stores. Glycine and L-arginine are metabolised to ornithine and 
guanidoacetate in the kidney, which is then processed in the liver to creatine and released in 
the circulation. In tissues and muscle, creatine is phosphorylated to phosphocreatine and 
serves as high-energy phosphate storage. Hydrolysis of the high energy phosphate bond in 
muscle leads to conversion to creatinine, which is then eliminated in urine. Measured urinary 
creatinine levels are normal suggesting that decreased glycine is not sufficient to affect its 
synthesis. 
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Urinary creatinine also serves as an indirect measurement of muscle mass, and muscle 
mostly metabolises branched-chain amino acids, the preferred substrates of B0AT1. The 
normal levels of urinary creatinine of ace2 null mice indicate that muscle metabolism is not 
affected by loss of intestinal B0AT1, as expected given the normal plasma levels of 
branched-chain amino acids. 
 
 
Plasma L-lysine 
 
The increase of plasma L-lysine is surprising as it is an essential amino acid, ruling out 
endogenous increases in synthesis. A plasma increase of L-lysine might be due to increased 
intestinal absorption or rather decreased peripheral tissue uptake or decreased metabolic 
processing. 
 
Degradation of L-lysine mainly takes place in the liver and mutations in genes involved in L-
lysine catabolism cause familial hyperlysinemia (ie. the α-aminoadipic semialdehyde 
synthase (AASS), the bifunctional protein that contains both lysine-ketoglutarate reductase 
(LKR) and saccharopine dehydrogenase (SDH)). Hyperammonemia, though the precise 
cause is not known, is additionally present in these patients leading to mental retardation and 
neuromuscular dysfunction (Chen, 2006).  
Though ace2 null mice do not exhibit symptoms caused by hyperammonemia, it is not known 
yet if there is a decrease of the activity of the enzymes involved in L-lysine catabolism or of 
L-lysine uptake by the liver. 
 
Another set of mutations leading to disturbances in L-lysine levels are found in amino acid 
transporter genes b0,+AT-rBAT (Slc7a9-Slc3a1) and y+LAT1-4F2hc (Slc7a7-Slc3a2). 
Intestinal uptake and renal re-uptake of cationic amino acids in exchange for neutral amino 
acids is mediated by the heteromeric amino acid transporters b0,+AT-rBAT on the apical side 
and y+LAT1-4F2hc on the basolateral side. 
The defect of the luminal transport leads to cystinuria (OMIM 220100), a condition divided in 
type A and type B that corresponds to mutations in rBAT and b0,+AT, respectively. The only 
clinical sign of cystinuria is the development of cystine crystals in the urinary tract leading to 
severe urolithiasis. The knock-out mouse model of Slc7a9 (b0,+AT) displays significantly 
lower levels of plasma L-lysine and cystine, and only a tendency to display lower L-arginine 
and ornithine levels. These four amino acids have higher excretion levels in the urine of 
Slc7a9 knock-out mice (Feliubadalo et al, 2003). Study of the Slc3a1 (rBAT) null mice 
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showed higher levels of L-lysine, L-arginine and ornithine in the urine of these mice and 
plasma amino acid levels were not measured (Peters et al, 2003). 
Similarly, mutations in y+LAT1 lead to lysinuric protein intolerance (LPI, OMIM 222700). The 
aetiology of LPI is the impaired (re-)absorption of cationic amino acids in small intestine and 
kidney, leading to decreased plasma levels and increased urine levels of cationic amino 
acids. Decreased levels of L-arginine and ornithine that serve as substrates for the urea 
cycle induce hyperammonemia. LPI is additionally characterised by vomiting, diarrhea, 
failure to thrive, growth retardation, hepatosplenomegaly, osteoporosis, episodes of coma 
and chronic renal disease (Sperandeo et al, 2007). Mutations of the associated protein 
Slc3a2 (4F2hc) have not been reported in association with LPI which is probably because 
the knock-out mouse model of Slc3a2 is embryonic lethal (Tsumura et al, 2003). 
Cationic amino acid levels in ace2 null mice mirror the situation found in the slc7a9 (b0,+AT) 
knock-out mice such that L-lysine is increased and L-arginine has a tendency to be higher.  
A increase in the activity of b0,+AT-rBAT is unlikely to rise plasma amino acid levels as dietary 
amino acids are almost entirely taken up by the small intestine, and b0,+AT expression levels 
at the membrane were not modified in the ace2 null mice (data not shown). It is however not 
known how the intracellular concentrations of amino acids are disturbed by the lack of B0AT1 
and how this affects the release of amino acids on the basolateral side, for example by 
y+LAT1-4F2hc. 
 
 
ACE2 association to other transporters 
 
It has been shown for  adaptor proteins that they might regulate transporters belonging to 
unrelated families and/or various functions, as in the case of PDZK1 that regulates PepT1 
(Slc15a1) and carnitine/organic cation transporter OCTN2 (Slc22a5) (Sugiura et al, 2008). 
Next to amino acid transport, unrelated membrane transport proteins like ion channels might 
be under the control of ACE2 expression, as suggested by their abnormal urinary ion levels. 
It remains to be seen whether sulphate transporter NaS1 that is expressed in ileum and in 
proximal tubule cells might be down- or up-regulated, respectively (Morris & Murer, 2001). 
Decreased urinary phosphate levels on the other hand might be due to increased expression 
of phosphate transporters NaPi-IIa/c (Slc34a1/3) in the kidney, or decreased NaPi-IIb 
(Slc34a2) in the ileum (Murer et al, 2004). Similar possibilities can be imagined concerning 
epithelial calcium channels TRPV5 and TRPV6 in the kidney and Mg2+ transporters (Boron & 
Boulpaep, 2005). 
However, a large part of the epithelial transport of ions can be through the paracellular route 
depending on the diet, possibly relying on tight junction proteins expression such as Claudin 
104 
16 for Mg2+ transport. Tubular ion reabsorption is also regulated by a variety of other 
parameters such as the acid-base balance, hormones (parathyroid hormone (PTH), ANP), 
vitamin D and the levels of other ions. For instance, PTH decreases kidney phosphate 
reabsorption, but increases calcium and magnesium reabsorption. Therefore it can not be at 
the origin of the ion disturbances observed in the urine of ace2 null mice since all these ions 
are increased (Boron & Boulpaep, 2005). 
In the absence of gross phenotype at the level of growth and skeleton, it is likely that the 
observed changes in urinary excretion are secondary to changes in intestinal absorption. 
 
 
The ace2 null mice display slower growth after weaning 
 
It is tempting to explain the slower growth of ace2 null mice by the absence of amino acid 
transporter B0AT1. The delay in growth would be secondary to decreased amino acid 
absorption due to the lack of B0AT1 that would only be compensated after adaptation to the 
switch from mother milk to pellet food. It remains unclear why the growth phenotype, if 
related to nutrient uptake, would only appear after weaning and if the growth defect is 
generalised or localised to certain organs. 
This might be explained by the richness of the mouse milk that contains high amounts of 
protein, about 10% vs. 0.9% in human milk and 3.3% in cow milk (Boron & Boulpaep, 2005; 
Hadsell et al, 2007). Similarly, LPI symptoms only appear after weaning due to the relatively 
low amounts of lysine in breast milk (Cimbalistiene et al, 2007). 
As mentioned before, the growth phenotype might also arise due to disturbances linked to 
the systemic role of ACE2 in the RAS though as yet most of the phenotype associated with 
increased levels of Ang II has primarily been observed in 6 months old animals. 
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10. Conclusion and Outlook 
 
The results presented in this thesis demonstrate the importance of tissue-specific associated 
proteins ACE2 and Tmem27 in intestinal and renal amino acid absorption and reabsorption, 
respectively. 
 
Our work with the ace2 and tmem27 knock-out mice models has shown that correct 
localisation of B0AT1 (Slc6a19) to the apical membrane is only possible when tissue-specific 
associated proteins ACE2 in small intestine enterocytes and homologue Tmem27 in kidney 
proximal tubule are expressed. Absence of ACE2 accordingly led to the abolition of 
functional Na+-dependant L-isoleucine transport. Co-immunoprecipitation of ACE2 with 
B0AT1 showed that ACE2 is not only necessary but also directly interacts with B0AT1 at the 
luminal membrane of enterocytes. 
Thus, ace2 and tmem27 null mice can be used to study the role of the neutral amino acid 
transporter B0AT1 in kidney and intestine independently. Further study of ace2 null mice 
evidenced a rather discrete phenotype with decreased plasma levels of L-tryptophan and 
glycine and increased plasma levels of L-lysine and urea. Though renal amino acid fractional 
excretion rates were normal, ace2 null mice exhibited disturbances in urinary pH and ions. 
Finally, the ace2 null mice grew more slowly after weaning leading to a lower weight at 8 
weeks. 
Furthermore co-expression of these associated proteins with the human orthologue of B0AT1 
in the heterologous X. laevis oocyte system increased the transport rate and the cell surface 
expression of the transporter. This allowed a more complete characterisation of wild-type and 
Hartnup-causing mutations of B0AT1, evidencing different classes of mutants. 
 
B0AT3 (Slc6a18), that is expressed in kidney late proximal tubule and not in small intestine 
needs association to Tmem27 for expression in vivo, similarly to its homologue B0AT1. 
However, only co-expression of ACE2 and not Tmem27 supported the functional expression 
of B0AT3 in X. laevis oocytes that enabled us to measure its function as a transporter of 
neutral amino acids. B0AT3 thereby exhibited a high affinity (K0.5 = 0.21 mM for L-Ile) Na+- 
and Cl--dependant transport of a broad range of neutral amino acids. 
Re-analysis of the slc6a18 mouse model after more than 10 generations of back-cross in the 
C57Bl/6 background confirmed aminoaciduria though strikingly, there was not only a 
substantial urinary loss of glycine (60-fold higher than in xt2+/+) but also of L-glutamine (20-
fold) and of all other neutral amino acids. This confirms the complementary role of B0AT3 to 
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B0AT1, reabsorbing the leftover tubular amino acids or the amino acids that backleak through 
the paracellular route in the late segments of the proximal tubule. 
In their original description, slc6a18 null mice displayed a significantly elevated blood 
pressure. We could however only observe a stress-sensitive hypertension and a stress-
induced increase in respiratory rate in slc6a18 null mice, suggesting a possible impact of the 
lack of this transporter on regulatory functions of the sympathetic nervous system or on 
circulating L-arginine levels thereby affecting NO synthesis. 
 
 
In conclusion, the association of intestinal B0AT1 with a key regulator of the RAAS is 
surprising, and raises many interesting questions regarding the role of ACE2 as a regulator 
of Ang II levels in the small intestine and the physiological relevance of its association with 
B0AT1. 
 
 
How is RAAS affecting nutrient transport in the small intestine ? 
 
It remains to be investigated whether luminal ACE2 regulates Ang II levels in the lumen of 
the small intestine and how this may affect amino acid transport and absorption of other 
substrates as well as enteric blood flow.  Additionally, ACE2 peptidase activity on ghrelin 
might also regulate enteric nutrient transport (Vickers et al, 2002). 
Such a broader effect is suggested by the regulation of glucose uptake by Ang II and by the 
modified glucose homeostasis of ace2 null mice (Niu et al, 2008). Incubation of increasing 
concentrations of Ang II decreased glucose uptake levels in intestinal ring segments, an 
effect that was inhibited by AT1 receptor antagonist losartan (Wong et al, 2007). This implies 
that if endogenously produced Ang II secreted in the lumen of the small intestine regulates 
SGLT1 expression, ace2 null mice will display higher concentrations of Ang II and therefore 
less glucose uptake. To further test this hypothesis, we will measure glucose uptake in 
intestine rings of ace2 null mice. Similarly, additional treatment of the mice with losartan and 
ACE inhibitors will show if Ang II levels affect glucose or amino acid uptake and if this is 
dependant on AT1 receptor. 
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Is ACE2 association to B0AT1 relevant ? 
 
It is hypothesised that ACE2 arose from an ancient chimeric gene duplication of ACE and 
Tmem27, which are both already present in the pufferfish (Chou et al, 2006; Mount, 2007). It 
is however not clear why ACE2 does not play a role on amino acid transport in kidney, and 
why ACE2 replaced the role of Tmem27 in small intestine. It could be relevant for an amino 
acid transporter to be associated to an exopeptidase, however the specificity of ACE2 for 
Pro-(1-3 residues)-Pro-hydrophobic amino acid patterns might be too high for meaningful 
substrate channelling. It is to be investigated whether other brush border peptidases or 
disaccharidases may, like ACE2, associate to other amino acid transporters or glucose 
transporters, respectively. 
 
 
Does ACE2 associate with other members of the SLC6 family ? 
 
It remains to be examined whether ACE2, like Tmem27, interacts with other amino acid 
transporters of the SLC6 family. The Na+ and Cl--dependant neutral and cationic amino acid 
transporter ATB0,+ (Slc6a14) is hypothesised to be expressed in rabbit ileum (Anderson et al, 
2008) and in human colon (Gupta et al, 2005). Considering that the Na+-dependant transport 
of L-isoleucine is absent in all segments of the small intestine of the ace2 null mice (data not 
shown), ATB0,+ might either be downregulated, or not expressed in mouse small intestine. 
Preliminary results show that luminal expression of the imino acid transporter SIT1 (Slc6a20) 
is decreased in the small intestine of ace2 null mice as seen by immunofluorescence. 
Though this interaction remains to be further characterised, testing of SIT1 functional 
expression by uptake of L-Proline in everted intestinal rings is promising. Additionally, results 
obtained by R. Vuille and Dr. S.M.R. Camargo by co-expressing human SIT1 with ACE2 in 
X. laevis oocytes suggest functional interaction of the two proteins. 
Given the expression of SIT1 in brain and lung, further focus will be aimed at its possible 
interaction with associated proteins ACE2 or Tmem27 in those tissues. 
 
 
The ace2 null mice – A model for Hartnup disorder ? 
 
Mutations in B0AT1 are the only known cause of Hartnup disorder, a condition which is 
characterised by neutral aminoaciduria and various other clinical symptoms such as pellagra-
like rash, cerebellar ataxia and other neurological dysfunctions that appear to mostly 
manifest in situations of protein-restricted diet. Though tmem27 null mice suffer from extreme 
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aminoaciduria due to the lack of renal B0AT1 and other transporters, plasma amino acid 
levels are not affected (Danilczyk et al, 2006). Additional Hartnup symptoms are therefore 
probably not caused by the renal defect in itself, and could be better studied with the ace2 
null mice. 
Indeed the defect of intestinal B0AT1 might suffice to lead to decreased plasma levels of L-
tryptophan, the precursor of niacin and serotonin, leading to neurological and dermal 
symptoms. It remains to be investigated how lower levels of circulating L-tryptophan affect 
tissue concentrations of this amino acid, and if this is sufficient to induce neurological and 
pellagra-like symptoms when combined with low-protein diets. 
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